KR20190079575A - Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same - Google Patents
Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same Download PDFInfo
- Publication number
- KR20190079575A KR20190079575A KR1020180170019A KR20180170019A KR20190079575A KR 20190079575 A KR20190079575 A KR 20190079575A KR 1020180170019 A KR1020180170019 A KR 1020180170019A KR 20180170019 A KR20180170019 A KR 20180170019A KR 20190079575 A KR20190079575 A KR 20190079575A
- Authority
- KR
- South Korea
- Prior art keywords
- recombinant yeast
- gene
- yeast
- pex34
- seq
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 160
- 210000003463 organelle Anatomy 0.000 title claims abstract description 49
- 150000003505 terpenes Chemical class 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims description 18
- 230000001413 cellular effect Effects 0.000 title description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 210000004027 cell Anatomy 0.000 claims abstract description 24
- 230000035772 mutation Effects 0.000 claims abstract description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 154
- 101100519636 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX34 gene Proteins 0.000 claims description 34
- 235000021466 carotenoid Nutrition 0.000 claims description 25
- 150000001747 carotenoids Chemical class 0.000 claims description 25
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 24
- 235000013734 beta-carotene Nutrition 0.000 claims description 24
- 239000011648 beta-carotene Substances 0.000 claims description 24
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 24
- 229960002747 betacarotene Drugs 0.000 claims description 24
- 210000002824 peroxisome Anatomy 0.000 claims description 24
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 24
- 101100003189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ATG36 gene Proteins 0.000 claims description 21
- 101150107962 pex11 gene Proteins 0.000 claims description 21
- 101150015692 PEX11A gene Proteins 0.000 claims description 19
- 102100040056 Peroxisomal membrane protein 11A Human genes 0.000 claims description 18
- 229930191978 Gibberellin Natural products 0.000 claims description 17
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 claims description 17
- 239000003448 gibberellin Substances 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 239000005995 Aluminium silicate Substances 0.000 claims description 9
- 235000012211 aluminium silicate Nutrition 0.000 claims description 9
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 9
- 238000012224 gene deletion Methods 0.000 claims description 8
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 claims description 7
- 108010066605 Geranylgeranyl-Diphosphate Geranylgeranyltransferase Proteins 0.000 claims description 7
- 241000222057 Xanthophyllomyces dendrorhous Species 0.000 claims description 7
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 claims description 6
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 6
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 6
- 101150091750 HMG1 gene Proteins 0.000 claims description 5
- 101000621749 Penicillium citrinum Peroxiredoxin Pen c 3 Proteins 0.000 claims description 5
- 241000198071 Saccharomyces cariocanus Species 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- 108010050416 peroxisomal membrane protein 34 Proteins 0.000 claims description 5
- ONVABDHFQKWOSV-UHFFFAOYSA-N 16-Phyllocladene Natural products C1CC(C2)C(=C)CC32CCC2C(C)(C)CCCC2(C)C31 ONVABDHFQKWOSV-UHFFFAOYSA-N 0.000 claims description 4
- 101150009591 ATG36 gene Proteins 0.000 claims description 4
- 101100178203 Arabidopsis thaliana HMGB3 gene Proteins 0.000 claims description 4
- 108010082399 Autophagy-Related Proteins Proteins 0.000 claims description 4
- 102000003954 Autophagy-Related Proteins Human genes 0.000 claims description 4
- 241000221778 Fusarium fujikuroi Species 0.000 claims description 4
- 108700010013 HMGB1 Proteins 0.000 claims description 4
- 101150021904 HMGB1 gene Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- ONVABDHFQKWOSV-HPUSYDDDSA-N ent-kaur-16-ene Chemical compound C1C[C@H](C2)C(=C)C[C@@]32CC[C@@H]2C(C)(C)CCC[C@@]2(C)[C@@H]31 ONVABDHFQKWOSV-HPUSYDDDSA-N 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 claims description 3
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 claims description 3
- JCAIWDXKLCEQEO-PGHZQYBFSA-K 5beta,9alpha,10alpha-labda-8(20),13-dien-15-yl diphosphate(3-) Chemical compound CC1(C)CCC[C@@]2(C)[C@H](CCC(/C)=C/COP([O-])(=O)OP([O-])([O-])=O)C(=C)CC[C@@H]21 JCAIWDXKLCEQEO-PGHZQYBFSA-K 0.000 claims description 3
- 101710095468 Cyclase Proteins 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- 241001123227 Saccharomyces pastorianus Species 0.000 claims description 3
- JCAIWDXKLCEQEO-MSVCPBRZSA-N ent-Copalyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC[C@H]1C(=C)CC[C@@H]2C(C)(C)CCC[C@]12C)/C)O JCAIWDXKLCEQEO-MSVCPBRZSA-N 0.000 claims description 3
- 235000011765 phytoene Nutrition 0.000 claims description 3
- 108010001545 phytoene dehydrogenase Proteins 0.000 claims description 3
- 101150111320 KS gene Proteins 0.000 claims description 2
- 241001159781 Kazachstania spencerorum Species 0.000 claims description 2
- 241000039979 Kazachstania turicensis Species 0.000 claims description 2
- 241001123232 Kazachstania unispora Species 0.000 claims description 2
- 241000965982 Kazachstania zonata Species 0.000 claims description 2
- 241000235087 Lachancea kluyveri Species 0.000 claims description 2
- 241001123224 Naumovozyma dairenensis Species 0.000 claims description 2
- 101150109364 PEX34 gene Proteins 0.000 claims description 2
- 241000877399 Saccharomyces chevalieri Species 0.000 claims description 2
- 241000877401 Saccharomyces ellipsoideus Species 0.000 claims description 2
- 241001063879 Saccharomyces eubayanus Species 0.000 claims description 2
- 241001407717 Saccharomyces norbensis Species 0.000 claims description 2
- 241001123228 Saccharomyces paradoxus Species 0.000 claims description 2
- 102000055207 HMGB1 Human genes 0.000 claims 1
- 241001480024 Kazachstania exigua Species 0.000 claims 1
- 241000235072 Saccharomyces bayanus Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 23
- 230000037353 metabolic pathway Effects 0.000 abstract description 6
- 102000003992 Peroxidases Human genes 0.000 abstract description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 abstract description 4
- 230000006798 recombination Effects 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 49
- 108090000790 Enzymes Proteins 0.000 description 34
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 34
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 34
- 102000004190 Enzymes Human genes 0.000 description 32
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 25
- 101150001810 TEAD1 gene Proteins 0.000 description 25
- 101150074253 TEF1 gene Proteins 0.000 description 25
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 25
- 239000013598 vector Substances 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000002609 medium Substances 0.000 description 18
- 101100356529 Candida albicans (strain SC5314 / ATCC MYA-2876) RFG1 gene Proteins 0.000 description 17
- 101100361174 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ROX1 gene Proteins 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 13
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000002207 metabolite Substances 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 101150050575 URA3 gene Proteins 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 8
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 8
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 239000000592 Artificial Cell Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000007222 ypd medium Substances 0.000 description 4
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 3
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 3
- 208000035404 Autolysis Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 3
- 241000223218 Fusarium Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 description 3
- 241000764238 Isis Species 0.000 description 3
- -1 Isoprenoid compounds Chemical class 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100036422 Speckle-type POZ protein Human genes 0.000 description 3
- 101100114901 Streptomyces griseus crtI gene Proteins 0.000 description 3
- 239000007978 cacodylate buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000009134 cell regulation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 101150000046 crtE gene Proteins 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000028043 self proteolysis Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101150007280 LEU2 gene Proteins 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 102100023072 Neurolysin, mitochondrial Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101100061456 Streptomyces griseus crtB gene Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 101150011633 crtI gene Proteins 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005061 intracellular organelle Anatomy 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011330 nucleic acid test Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001550 polyprenyl Polymers 0.000 description 2
- 125000001185 polyprenyl group Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003535 tetraterpenes Chemical class 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 150000003735 xanthophylls Chemical class 0.000 description 2
- 235000008210 xanthophylls Nutrition 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 101710118787 Autophagy-related protein 36 Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000206911 Candida holmii Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150014925 POT1 gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101100127715 Phaffia rhodozyma crtYB gene Proteins 0.000 description 1
- 101710173432 Phytoene synthase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000582914 Saccharomyces uvarum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241001000247 Xanthophyllomyces Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
- C12P5/007—Preparation of hydrocarbons or halogenated hydrocarbons containing one or more isoprene units, i.e. terpenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
- C12Y103/99031—Phytoene desaturase (lycopene-forming) (1.3.99.31)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01001—Dimethylallyltranstransferase (2.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01032—15-Cis-phytoene synthase (2.5.1.32)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y505/00—Intramolecular lyases (5.5)
- C12Y505/01—Intramolecular lyases (5.5.1)
- C12Y505/01019—Lycopene beta-cyclase (5.5.1.19)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 유전자 조작을 통하여 세포 소기관이 변이된 재조합 효모 및 이를 이용한 다양한 아이소프레노이드 생산 방법에 관한 것이다. 유전자 재조합을 통해 세포 소기관인 퍼옥시좀의 개수 또는 크기가 증가된 변이된 효모에 유용산물인 아이소프레노이드 대사 경로를 도입하는 경우, 세포 소기관 변이가 없는 효모에 비하여 아이소프레노이드 생산량을 현저하게 증대시킬 수 있어 아이소프레노이드의 대량 생산이 가능하며, 이를 통해 아이소프레노이드가 적용되는 다양한 산업 분야에 유용하게 활용 가능하다. The present invention relates to a recombinant yeast in which cell organelles are mutated through gene manipulation, and a method for producing various isoprenoids using the recombinant yeast. The introduction of the isoprenoid metabolic pathway, a useful product in mutant yeasts with an increased number or size of peroxidase, the organelle of the cell through genetic recombination, significantly increased isoprenoid production compared to yeast without cell organelle mutation And can mass-produce isoprenoids. Thus, it is useful for various industrial fields to which isoprenoid is applied.
Description
본 발명은 유전자 조작을 통하여 세포 소기관이 변이된 재조합 효모 및 이를 이용한 다양한 아이소프레노이드 생산 방법에 관한 것이다. The present invention relates to a recombinant yeast in which cell organelles are mutated through gene manipulation, and a method for producing various isoprenoids using the recombinant yeast.
기능성 대사 경로를 조절하는 작업은 비효율적 조절 반응, 최적화되지 않은 물리화학적 환경, 경쟁 대사에 대한 대사중간물질의 손실, 대사산물 독성 등 여러가지 문제를 야기한다. 효모는 낮은 pH에서의 성장, 단순한 영양 요구, 바이러스 감염에 대한 낮은 확률 및 기질 및 대사산물 독성에 대한 높은 내성으로 인해 선호되는 산업 유기체이며, 유전자 조작의 용이성, 복잡한 이종 효소들의 발현 능력이 손쉬운 장점이 있다. 효모 대사 공학은 주로 세포질에서 대사 경로를 구축함에 집중되어왔다. 단백질 융합 및 합성 단백질 스케폴드와 같은 대사 경로 최적화 전략은 일부 대사 조절에 따른 생산성을 효과적으로 향상시킬 수 있으나, 스케폴드에 구축 가능한 효소의 수는 이용 가능한 결합 도메인에 의해 제한되며, 단백질 융합체와 스케폴드는 효소 활성에 부정적 영향을 미친다. 따라서 이를 극복하기 위한 다양한 전략이 연구되고 있다.Control of functional metabolic pathways leads to various problems such as ineffective regulatory reactions, unoptimized physicochemical environment, loss of metabolic intermediates to competitive metabolism, metabolic toxicity. Yeast is the preferred industrial organism due to its low pH growth, simple nutritional requirements, low probability for viral infections and high resistance to substrate and metabolite toxicity, ease of gene manipulation, and ability to express complex heterologous enzymes . Yeast metabolism has been concentrated mainly on the metabolic pathway in the cytoplasm. Metabolic pathway optimization strategies, such as protein fusion and synthetic protein scaffolds, can effectively improve productivity due to some metabolic regulation, but the number of enzymes that can be built into the scaffold is limited by available binding domains, Has a negative effect on the enzyme activity. Therefore, various strategies to overcome this are being studied.
아이소프레노이드는 테르페노이드(der-penoid), 테르펜(terpene)이라고도 불리는 이소프렌을 구성단위로 하는 유기화합물을 총칭하는 것을 말한다. 천연고무(gum) 등인 탄수화물 이외에 말단관능기가 알코올, 알데히드, 카르복실산(carboxylic acid) 또는 피로인산이 된 화합물이 식물세포 또는 동물세포 내에 나타나는 것으로 알려져 있다. 구성 이소프렌 단위(C5)의 수에 따라 모노테르펜(C10), 세스키테르펜(C15), 디테르펜(C20), 트리테르펜(C30), 테트라테르펜(C40) 등으로 분류하기도 한다. Isoprenoid refers to an organic compound containing isoprene as a constituent unit, which is also called "der-penoid" or "terpene". In addition to carbohydrates such as natural gums, compounds in which the terminal functional groups are alcohol, aldehyde, carboxylic acid or pyrophosphoric acid are known to appear in plant cells or animal cells. Depending on the number of constituent isoprene units (C5), monoterpene (C10), sesquiterpene (C15), diterpene (C20), triterpene (C30) and tetra terpene (C40) are also classified.
이소프레노이드 화합물은 23,000가지 이상이 알려져 있는 화학적으로 매우 다양한 물질이다. 이들 화합물 중 대표적인 물질은 콜레스테롤, 퀴논(quinone), 카로티노이드, polyprenyl phosphate와 고무 등으로 기능은 물론 구조에 있어서도 다양성을 보여준다. 11개의 isoprene으로 이루어진 polyprenyl phosphate 는 원핵 세포의 세포벽 합성에 직접 관여한다. Isoprenoid compounds are a very chemically diverse substance with more than 23,000 known. Representative materials of these compounds are cholesterol, quinone, carotenoid, polyprenyl phosphate and rubber, which show diversity in function as well as structure. Polyprenyl phosphate, which is composed of 11 isoprene, is directly involved in the synthesis of prokaryotic cell walls.
아이소프레노이드는 상업적으로 매우 중요한 형태의 지질이며, 탁월한 윤활성, 산화적 안정성, 낮은 유동점, 낮은 빙점, 수월한 생분해성을 가지고 있다. 또한 동물은 아이소프레노이드의 일종인 카로티노이드를 합성할 수 없기 때문에 반드시 음식을 통해 섭취해야만 한다. 이와 같은 아이소프레노이드의 중요성 및 필요성 때문에, 보다 손쉽게 아이소프레노이드를 제공하기 위하여 인공적으로 합성하거나 일부 조류에서 추출하는 방법이 연구되었고, 최근에는 유전체학과 생물정보학의 발달에 힘입어 미생물세포를 이용한 대사공학적인 대량생산 방법이 시도되고 있다.Isoprenoid is a commercially important form of lipid and has excellent lubricity, oxidative stability, low pour point, low freezing point, and easy biodegradability. In addition, animals can not synthesize carotenoids, one of the isoprenoids, and therefore must be ingested through food. Due to the importance and necessity of such isoprenoids, a method of artificially synthesizing or extracting from some algae has been studied in order to provide isoprenoids more easily. Recently, with the development of genomics and bioinformatics, metabolism using microbial cells Technological mass production methods are being tried.
그러나 아직까지 아이소프레노이드를 효과적으로 생산할 수 있도록 대사공정이 변경된 미생물이 널리 보고되지 않았으며, 이에 대한 연구의 필요성이 있다. However, microorganisms whose metabolic processes have been altered so as to produce isoprenoids have not been widely reported, and there is a need for further studies.
이에 본 발명자들은 아이소프레노이드를 효과적으로 생산할 수 있는 방법을 연구하던 중, 효모의 세포 소기관을 변이시키고, 아이소프레노이드 생산 관련 대사 공정에 변이를 유발하는 경우, 보다 효과적으로 다양한 아이소프레노이드 생산을 달성할 수 있음을 확인하고 본 발명을 완성하였다. Therefore, the inventors of the present invention have studied how to effectively produce isoprenoids. When the yeast cell organelles are mutated and mutations are caused in the isoprenoid production-related metabolism process, various isoprenoid production is more effectively achieved And the present invention has been completed.
따라서 본 발명의 목적은 세포 소기관 조절을 통해 아이소프레노이드의 생산능이 향상될 수 있도록 유전자 조작된 재조합 효모 및 이를 이용한 아이소프레노이드 생산 방법을 제공하는 것이다. Accordingly, an object of the present invention is to provide a genetically engineered recombinant yeast and a method for producing isoprenoid using the genetically modified yeast so that the productivity of isoprenoid can be improved through regulation of cell organelles.
상기와 같은 과제를 해결하기 위해, 본 발명은 PEX34 (Peroxisomal membrane protein 34) 유전자의 과발현, PEX11 (Peroxisomal membrane protein 11) 유전자의 결실 및 ATG36 (Peroxisome autophagy-related protein 36) 유전자의 결실로 이루어진 군에서 선택된 1종 이상의 유전자 변이가 도입된, 세포 소기관이 변이된 재조합 효모를 제공한다. In order to solve the problems as described above, the present invention PEX34 (Peroxisomal membrane protein 34) overexpression, PEX11 (Peroxisomal membrane protein 11) gene deletion and ATG36 And a deletion of a gene encoding a peroxisome autophagy-related protein (36) gene in a cell organelle-transformed recombinant yeast.
또한 본 발명은 상기 세포 소기관이 변이된 재조합 효모에 i) tHMG1 (truncated hydroxy-methyl glutaryl-CoA reductase), CrtE (Geranylgeranyl pyrophosphate synthase) CrtYB (Phytoene synthase-lycopene cyclase), CrtI (Phytoene desaturase) 유전자 세트 및 ii) tHMG1, CrtE, CDPS /KS (ent-copalyl diphosphate/kaurene synthase) 유전자 세트로 이루어진 군에서 선택된 1종의 유전자 세트가 도입된 아이소프레노이드 생산성이 증대된 재조합 효모를 제공한다. In another aspect, the present invention i) tHMG1 (truncated hydroxy-methyl glutaryl-CoA reductase), CrtE (Geranylgeranyl pyrophosphate synthase in the recombinant yeast is the organelle mutations) CrtYB (Phytoene synthase-lycopene cyclase), CrtI ( Phytoene desaturase) Gene set, and ii) tHMG1, CrtE , And a set of genes selected from the group consisting of a CDPS / KS (ent-copalyl diphosphate / kaurene synthase) gene set is introduced into a recombinant yeast strain having increased isoprenoid productivity.
또한 본 발명은 상기 아이소프레노이드 생산성이 증대된 재조합 효모를 배양하는 단계; 를 포함하는 아이소프레노이드 생산 방법을 제공한다. The present invention also provides a method for producing a recombinant yeast, comprising culturing the recombinant yeast having increased isoprenoid productivity; ≪ RTI ID = 0.0 > isoprenoid < / RTI >
유전자 재조합을 통해 세포 소기관인 퍼옥시좀의 개수 또는 크기가 증가된 변이된 효모에 유용산물인 아이소프레노이드 대사 경로를 도입하는 경우, 세포 소기관 변이가 없는 효모에 비하여 아이소프레노이드 생산량을 현저하게 증대시킬 수 있어 아이소프레노이드의 대량 생산이 가능하며, 이를 통해 아이소프레노이드가 적용되는 다양한 산업 분야에 유용하게 활용 가능하다. The introduction of the isoprenoid metabolic pathway, a useful product in mutant yeasts with an increased number or size of peroxidase, the organelle of the cell through genetic recombination, significantly increased isoprenoid production compared to yeast without cell organelle mutation And can mass-produce isoprenoids. Thus, it is useful for various industrial fields to which isoprenoid is applied.
도 1은 인위적 세포 소기관 조절능 부여에 의해 퍼옥시좀 (peroxisome) 의 수와 크기가 증가된 변이를 갖는 재조합 효모의 모식도이다.
도 2는 녹색 형광 단백질 (GFP)를 이용해 인위적 세포 소기관 조절능을 가지는 재조합 효모에서의 퍼옥시좀의 개수와 크기 변화를 확인한 결과를 나타낸 도이다.
도 3은 에너지 여과 투과전자현미경을 통해 인위적 세포 소기관 조절능을 갖는 재조합 효모의 구조 변화를 확인한 결과를 나타낸 도이다.
도 4는 카로티노이드 중 하나인 베타카로틴 생합성 대사 경로의 모식도이다.
도 5는 대조군 효모 CEN-βCN과 인위적 세포 소기관 조절능을 갖는 재조합 효모를 형질전환시킨 베타카로틴 발현 균체(A), PX1-βCN의 균주 성장 곡선(B), 및 베타카로틴 생산량 비교(C) 결과를 나타낸 도이다.
도 6은 지베렐린 대사물질 중 하나인 카우린 생합성 대사 경로의 모식도이다.
도 7은 대조군 효모 CEN-KRN과 인위적 세포 소기관 조절능을 갖는 재조합 효모를 형질전환시킨 PX1-KRN의 균주 성장 곡선(A) 및 카우린 생산량 비교(B) 결과를 나타낸 도이다.FIG. 1 is a schematic diagram of a recombinant yeast having an increased number and size of peroxisome by the regulation of an artificial cellular organelle regulation.
FIG. 2 shows the results of confirming the number and size of peroxisome in a recombinant yeast having an artificial cellular organelles regulating ability by using a green fluorescent protein (GFP). FIG.
FIG. 3 is a diagram showing the result of confirming the structural change of a recombinant yeast having an artificial cellular organelles regulating ability through an energy filtration transmission electron microscope.
Figure 4 is a schematic diagram of the beta carotene biosynthetic pathway, one of the carotenoids.
FIG. 5 is a graph showing the growth curves (B) and beta-carotene yields (C) of the β-carotene-expressing cells (A), PX1-βCN transformed with the control yeast CEN-βCN and recombinant yeast Fig.
Figure 6 is a schematic diagram of the kaurin biosynthetic pathway, one of the gibberellin metabolites.
FIG. 7 is a graph showing the results of the strain growth (A) and the kaolin production (B) of PX1-KRN transformed with a control yeast CEN-KRN and a recombinant yeast having an artificial cellular organelles regulating ability.
본 발명은 PEX34 (Peroxisomal membrane protein 34) 유전자의 과발현, PEX11 (Peroxisomal membrane protein 11) 유전자의 결실 및 ATG36 (Peroxisome autophagy-related protein 36) 유전자의 결실로 이루어진 군에서 선택된 1종 이상의 유전자 변이가 도입된, 세포 소기관이 변이된 재조합 효모를 제공한다. The present invention relates to PEX34 (Peroxisomal membrane protein 34) gene, deletion of PEX11 (Peroxisomal membrane protein 11) gene and ATG36 And a deletion of a gene encoding a peroxisome autophagy-related protein (36) gene in a cell organelle-transformed recombinant yeast.
본 발명에 있어서, '세포 소기관 변이' 란, 상기와 같은 유전자 변이의 도입에 의하여 종래 야생형 효모 대비 퍼옥시좀 (peroxisome)의 개수 또는 크기가 증가된 변이를 의미한다. 따라서 본 발명의 세포 소기관의 변이는 퍼옥시좀의 개수 또는 크기 증대일 수 있다. 퍼옥시좀은 세포 내 소기관의 하나로 내부에 산화효소와 카탈라아제를 포함하며, 산화작용을 통해 과산화수소를 생성하고 과산화수소를 물로 전환시키는 역할을 한다. In the present invention, 'organellular transformation' refers to a variation in the number or size of peroxisome compared to the wild type yeast by introduction of the gene mutation as described above. Thus, the variation of the organelle of the present invention may be an increase in the number or size of peroxisome. Peroxisome is one of the intracellular organelles, which contains oxidase and catalase in the inside, and produces hydrogen peroxide through oxidation and converts hydrogen peroxide into water.
본 발명에 있어, 세포 소기관 변이를 갖는 인위적 세포 소기관 조절능을 갖는 재조합 효모는 PEX34 (Peroxisomal membrane protein 34) 유전자의 과발현, PEX11 (Peroxisomal membrane protein 11) 유전자의 결실 및 ATG36 (Peroxisome autophagy-related protein 36) 유전자의 결실로 이루어진 군에서 선택된 1종 이상의 유전자 변이가 도입된 효모일 수 있고, 상기 PEX34 (NCBI number: 850302), PEX11 (NCBI number: 854018) 및 ATG36 (NCBI number: 853254) 유전자는 사카로마이세스 세레비지에(Saccharomyces cerevisiae) 유래의 유전자일 수 있다. In the present invention, the recombinant yeast having an artificial cellular organotactic control ability having cell organelle mutation is PEX34 (Peroxisomal membrane protein 34) gene, deletion of PEX11 (Peroxisomal membrane protein 11) gene and ATG36 And a deletion of a gene encoding a peroxisome autophagy-related protein (36) gene, and the PEX34 (NCBI number: 850302) , PEX11 (NCBI number: 854018) And ATG36 (NCBI number: 853254) The gene was introduced into Saccharomyces cerevisiae cerevisiae . < / RTI >
본 발명의 바람직한 예에서, 상기 세포 소기관이 변이된 재조합 효모는 i) ATG36 유전자가 결실된 재조합 효모, ii) PEX34 유전자가 과발현된 재조합 효모, iii) PEX11 유전자 결실 및 PEX34 유전자가 과발현된 재조합 효모 및 iv) PEX11 유전자 결실, ATG36 유전자 결실 및 PEX34 유전자가 과발현된 재조합 효모로 이루어진 군에서 선택된 1종의 효모일 수 있다. In a preferred embodiment of the present invention, the cell organelles are mutated in a recombinant yeast, i) a recombinant yeast in which the ATG36 gene is deleted, ii) PEX34 Recombinant yeast overexpressing the gene, iii) PEX11 Gene deletion and PEX34 Recombinant yeast overexpressing the gene and iv) PEX11 Gene deletion, ATG36 gene deletion and PEX34 And a recombinant yeast in which the gene is over-expressed.
상기 i 내지 iv 의 재조합 효모들은 모두 다양한 형태의 변화된 세포 소기관을 가지고 있으며, 바람직하게는 야생형 효모 대비 퍼옥시좀의 크기 및/또는 개수가 증대된 특징을 나타낼 수 있다. 또한 i 내지 iv 의 재조합 효모들은 모두 세포 소기관이 변이됨으로써, 이에 아이소프레노이드 관련 생합성 대사를 도입하는 경우 세포 소기관이 변이되지 않은 야생형 효모와 비교하여 보다 향상된 아이소프레노이드 생산능을 나타낼 수 있다. 따라서 본 발명의 세포 소기관이 변이된 재조합 효모는 아이소프레노이드 생산 용도로 사용될 수 있다. All of the recombinant yeasts of i to iv have various types of modified organelles, and preferably, the size and / or number of peroxisome is increased compared to the wild type yeast. In addition, the recombinant yeasts i to iv all exhibit improved isoprenoid production ability as compared with the wild-type yeast in which cell organelles are not mutated when introducing isoprenoid-related biosynthetic metabolism into cell organelles. Therefore, the organelle-transformed recombinant yeast of the present invention can be used for production of isoprenoid.
본 발명에 있어, 상기 재조합 효모는 상기 유전자의 변이에 의하여 세포 소기관의 변이를 달성할 수 있는 효모를 제한없이 포함하며, 바람직하게는 사카로마이세스 세레비지애(S. cerevisiae), 사카로마이세스 바야누스(S.bayanus), 사카로마이세스 보울라디(S. boulardii), 사카로마이세스 불데리(S. bulderi), 사카로마이세스 카리오카누스(S. cariocanus), 사카로마이세스 카리오쿠스(S. cariocus), 사카로마이세스 체발리에리(S.chevalieri), 사카로마이세스 다이레넨시스(S. dairenensis), 사카로마이세스 엘립소이데우스(S.ellipsoideus), 사카로마이세스 유바야뉴스(S. eubayanus), 사카로마이세스 엑시거스(S. exiguus), 사카로마이세스 플로렌티누스(S. florentinus), 사카로마이세스 클루이베리(S. kluyveri), 사카로마이세스 마티니에(S.martiniae), 사카로마이세스 모나센시스(S. monacensis), 사카로마이세스 노르벤시스(S. norbensis), 사카로마이세스 파라독서스(S. paradoxus), 사카로마이세스 파스토리아누스(S. pastorianus), 사카로마이세스 스펜서로룸(S. spencerorum), 사카로마이세스 투리센시스(S. turicensis), 사카로마이세스 우니스포루스(S.unisporus), 사카로마이세스 우바룸(S. uvarum), 및 사카로마이세스 조나투스(S. zonatus)로 이루어진 군에서 선택된 1종인 것을 특징으로 할 수 있다. In the present invention, the recombinant yeast is not limited to yeast capable of achieving mutation of cell organelles by the mutation of the gene, and preferably includes S. cerevisiae, S. boulardii, S. bulderi, S. cariocanus, Scharomyces cerevisiae, S. aureus, and the like, S. cariocus, S. chevalieri, S. dairenensis, S. ellipsoideus, S. cerevisiae, S. eubayanus, S. exiguus, S. florentinus, S. kluyveri, Sakae, and the like. S. martiniae, S. monacensis, < RTI ID = 0.0 > SACARAMI < S. norbensis, S. paradoxus, S. pastorianus, S. spencerorum, and Sarkaromyces spp. In the case of S. turicensis, S. unisporus, S. uvarum, and S. zonatus, And one kind selected from the group consisting of
본 발명은 또한, 상기 세포 소기관이 변이된 재조합 효모에 아이소프레노이드 관련 생합성 경로를 도입하여, 아이소프레노이드 생산성이 증대된 재조합 효모를 제공한다. The present invention also provides a recombinant yeast with increased isoprenoid productivity by introducing an isoprenoid-related biosynthetic pathway into the recombinant yeast transformed with the cell organelles.
상기 아이소프레노이드 생산성이 증대된 재조합 효모는 i) tHMG1 (truncated hydroxy-methyl glutaryl-CoA reductase, CrtE (Geranylgeranyl pyrophosphate synthase), CrtYB (Phytoene synthase-lycopene cyclase) 및 CrtI (Phytoene desaturase) 유전자 세트 및 ii) tHMG1, CrtE 및 CDPS /KS (ent-copalyl diphosphate/kaurene synthase) 유전자 세트로 이루어진 군에서 선택된 1종의 유전자 세트가 도입된 아이소프레노이드 생산성이 증대된 재조합 효모일 수 있다. The isofrenoid productivity of the recombinant yeast is increased by: i) truncated hydroxy-methyl glutaryl-CoA reductase ( tHMG1 ) CrtE ( Geranylgeranyl pyrophosphate synthase), CrtYB (Phytoene synthase-lycopene cyclase) and CrtI ( Phytoene desaturase) Gene set, and ii) tHMG1, CrtE and And a set of genes selected from the group consisting of CDPS / KS (ent-copalyl diphosphate / kaurene synthase) gene set is introduced into a recombinant yeast having increased isoprenoid productivity.
본 발명의 재조합 효모를 이용하면, 카로티노이드 중 하나인 베타 카로틴, 지베렐린 대사 물질 중 하나인 카우린 생산능을 증가시킬 수 있으므로, 상기 유전자 세트의 도입 및 세포 소기관 변이에 따라 아이소프레노이드 생산능이 증대됨을 확인할 수 있다. The use of the recombinant yeast of the present invention can increase the ability of kaurin, one of the carotenoids, beta-carotene and gibberellin metabolites, to increase the ability to produce isoprenoid according to the introduction of the gene set and the variation of cell organelles Can be confirmed.
본 발명에 있어 아이소프레노이드는 본 발명의 유전자 세트 도입에 따라 생산이 증대될 수 있는 다양한 당 분야에 공지된 아이소프레노이드를 포함할 수 있으나, 바람직하게는 베타 카로틴, 카우린, 카로티노이드 또는 지베렐린인 것을 특징으로 할 수 있다. In the present invention, isoprenoids may include a variety of isoprenoids known in the art that can be increased in production upon introduction of the gene set of the present invention, but preferably beta-carotene, kaurin, carotinoid or gibberellin . ≪ / RTI >
본 발명의 유전자 세트에 포함되는 tHMG1 (NCBI number: 854900)은 사카로마이세스 세레비지에 유래이며, 상기 CrtE (NCBI number: DQ016502) , CrtYB (NCBI number: AY177204) 및 CrtI (NCBI number: KR779665) 는 잔토필로마이시스 덴드로하우스(xanthophyllomyces dendrorhous) 유래이고, 상기 CDPS /KS (NCBI number: AB013295) 는 푸자리움 푸지쿠로이(Fusarium fujikuroi) 유래인 것을 특징으로 할 수 있다. The tHMG1 gene contained in the gene set of the present invention (NCBI number: 854900) is derived from Saccharomyces cerevisiae, and the CrtE (NCBI number: DQ016502) , CrtYB (NCBI number: AY177204) And CrtI (NCBI number: KR779665) is derived from xanthophyllomyces dendrorhous , and the CDPS / KS (NCBI number: AB013295) is derived from Fusarium fujikuroi . < / RTI >
본 발명에 있어, 상기 재조합 효모는 i) tHMG1 , CrtE , CrtYB 및 CrtI 유전자 세트가 도입된 효모일 수 있으며, 상기 유전자 세트가 도입된 효모는 카로티노이드 중 하나인 베타 카로틴의 생산성이 증대되고, 따라서, 상기 유전자 세트가 도입된 효모를 이용하면 아이소프레노이드 중 카로티노이드의 생산성이 증대될 수 있다. In the present invention, the recombinant yeast is preferably selected from the group consisting of i) tHMG1 , CrtE , CrtYB And CrtI gene set, and the yeast into which the gene set is introduced increases the productivity of beta carotene, which is one of the carotenoids. Therefore, when the yeast into which the gene set is introduced is used, the productivity of carotenoids in isoprenoid Can be increased.
본 발명에 있어, 상기 재조합 효모는 ii) tHMG1 , CrtE 및 CDPS /KS 유전자 세트가 도입된 효모일 수 있으며, 상기 유전자 세트가 도입된 효모는 지베렐린의 대사산물인 카우린의 생산성이 증대되고, 따라서, 상기 유전자 세트가 도입된 효모를 이용하면 아이소프레노이드 중 지베렐린의 생산성이 증대될 수 있다. In the present invention, the recombinant yeast is selected from the group consisting of ii) tHMG1 , CrtE and The yeast in which the CDPS / KS gene set has been introduced can be used, and the yeast into which the gene set is introduced increases the productivity of kaurin, a metabolite of gibberellin. Therefore, when the yeast in which the gene set is introduced, The productivity of gibberellin can be increased.
본 발명의 재조합 효모를 제조하기 위하여, 당 분야에 알려진 통상의 방법을 이용하여 유전자 재조합 방법을 이용할 수 있고, 예컨대 상기 관련 유전자들을 적절한 발현 벡터에 삽입하여 도입하는 방법을 이용할 수 있다. 이 때 발현 벡터로는 선택된 숙주 미생물에 통상적으로 사용하는 발현 벡터는 어느 것이나 사용 가능하며, 예를 들면 플라스미드, 코즈미드, 파지 입자 및 바이러스 벡터로 이루어진 군에서 선택된 1종 이상의 벡터를 이용할 수 있고, 보다 바람직하게는 pRS series, YEplac series, 및 pCEV series 등의 당 업계에 상용화된 벡터를 이용할 수 있다. 재조합 벡터와의 작동적 연결은 당해 기술분야에서 잘 알려진 유전자 재조합 기술을 이용하여 제조할 수 있으며, 부위-특이적 DNA 절단 및 연결은 당해 기술 분야에서 일반적으로 알려진 효소 등을 사용한다.In order to produce the recombinant yeast of the present invention, a recombinant method can be used by a conventional method known in the art. For example, a method of introducing the relevant genes into an appropriate expression vector and introducing the recombinant yeast can be used. As the expression vector, any expression vector conventionally used for the selected host microorganism can be used. For example, one or more vectors selected from the group consisting of plasmid, cosmid, phage particle and viral vector can be used, More preferably, pRS series, YEplac series, and pCEV series can be used. The operative linkage with the recombinant vector can be produced using genetic recombination techniques well known in the art, and site-specific DNA cleavage and linkage are made using enzymes generally known in the art.
본 발명에서 아이소프레노이드 생합성 관련 효소들을 암호화하는 유전자들은 유전체 상에 직접 도입될 수 있으며, 해당 유전자 조합을 구성하는 유전자들 중 일부는 세포 소기관 조절 효모의 염색체 상에 직접 도입시키고 나머지는 벡터에 삽입하여 도입시킬 수 있다. 이러한 염색체상에 도입시키는 방법으로는 이에 제한되는 것은 아니나 통상적으로 사용되는 상동성 재조합 (Homologous recombination) 또는 CRISPR Cas9 과 같은 공지의 방법들을 이용할 수 있다.In the present invention, genes encoding isoprenoid biosynthesis-related enzymes can be introduced directly onto the genome, and some of the genes constituting the corresponding gene combination are directly introduced into the chromosome of the cell organelle-regulating yeast, . Methods for introducing the cDNA on such chromosomes include, but are not limited to, conventional methods such as homologous recombination or CRISPR Cas9.
또한 본 발명은 상기 재조합 효모를 배양하는 단계; 를 포함하는 아이소프레노이드 생산 방법을 제공하며, 앞서 기술한 내용과의 중복을 피하기 위해 중복되는 설명에 대해서 생략한다. The present invention also relates to a method for producing a recombinant yeast, comprising: culturing the recombinant yeast; The present invention will now be described in detail with reference to the accompanying drawings, in which like reference characters designate the same or similar parts throughout the lifespan.
본 발명에 있어서, "배양"은 미생물을 적당히 인공적으로 조절한 환경조건에서 생육시키는 것을 의미한다. In the present invention, "cultivation" means that microorganisms are grown under moderately artificially controlled environmental conditions.
본 발명의 방법에 있어, 상기 재조합 효모는 세포 내 소기관이 변이된 효모이며, 이를 통해 도입된 아이소프레노이드 생합성 경로의 효율이 증가됨에 따라 목적하는 아이소프레노이드를 더욱 높은 효율로 생산될 수 있도록 할 수 있다. In the method of the present invention, the recombinant yeast is a yeast in which the intracellular organelles are mutated, and the efficiency of the introduced isoprenoid biosynthesis pathway is increased, so that the desired isoprenoid can be produced with higher efficiency .
상기 효모는 통상의 배지에서 생육 가능하며, 일 예로 뉴트리엔트 브로스(Nutrient broth) 배지에서 배양할 수 있다. 상기 배지는 특정 미생물을 배양하기 위하여 배양대상 즉 배양체가 되는 미생물이 필요로 하는 영양물질을 포함하는 것으로 특수한 목적을 위한 물질이 추가로 첨가되어 혼합된 것일 수 있다. 상기 배지는 배양기 또는 배양액이라고도 하며, 천연배지, 합성배지 또는 선택배지를 모두 포함하는 개념이다. The yeast can be grown in a conventional medium, for example, in a nutrient broth medium. The culture medium may contain nutrients required for culturing, that is, a microorganism to be cultured in order to cultivate a specific microorganism, and may be a mixture in which a substance for a special purpose is further added and mixed. The medium is also referred to as an incubator or a culture medium, and is a concept including both natural medium, synthetic medium and selective medium.
배양에 사용되는 배지는 적당한 탄소원, 질소원, 아미노산, 비타민 등을 함유한 통상의 배지 내에서 온도, pH 등을 조절하면서 적절한 방식으로 특정 균주의 요건을 충족해야 한다. 사용될 수 있는 탄소원으로는 글루코즈 및 자일로즈의 혼합당을 주 탄소원으로 사용하며 이외에 수크로즈, 락토즈, 프락토즈, 말토즈, 전분, 셀룰로즈와 같은 당 및 탄수화물, 대두유, 해바라기유, 피마자유, 코코넛유 등과 같은 오일 및 지방, 팔미트산, 스테아린산, 리놀레산과 같은 지방산, 글리세롤, 에탄올과 같은 알코올, 아세트산과 같은 유기산이 포함된다. 이들 물질은 개별적으로 또는 혼합물로서 사용될 수 있다. 사용될 수 있는 질소원으로는 암모니아, 황산암모늄, 염화암모늄, 초산암모늄, 인산암모늄, 탄산안모늄, 및 질산암모늄과 같은 무기질소원; 글루탐산, 메티오닌, 글루타민과 같은 아미노산 및 펩톤, NZ-아민, 육류 추출물, 효모 추출물, 맥아 추출물, 옥수수 침지액, 카세인 가수분해물, 어류 또는 그의 분해생성물, 탈지 대두 케이크 또는 그의 분해생성물 등 유기질소원이 사용될 수 있다. 이들 질소원은 단독 또는 조합되어 사용될 수 있다. 상기 배지에는 인원으로서 인산 제1칼륨, 인산 제2칼륨 및 대응되는 소듐-함유 염이 포함될 수 있다. 사용될 수 있는 인원으로는 인산이수소칼륨 또는 인산수소이칼륨 또는 상응하는 나트륨-함유 염이 포함된다. 또한, 무기화합물로는 염화나트륨, 염화칼슘, 염화철, 황산마그네슘, 황산철, 황산망간 및 탄산칼슘 등이 사용될 수 있다. 마지막으로, 상기 물질에 더하여 아미노산 및 비타민과 같은 필수 성장 물질이 사용될 수 있다. 바람직한 배양배지는 예컨대 LB, YT 또는 M9 배지일 수 있으며, 이는 형질전환체의 생장을 위한 배지이다.The medium used for cultivation should meet the requirements of a specific strain in a suitable manner while controlling temperature, pH, etc. in a conventional medium containing a suitable carbon source, nitrogen source, amino acid, vitamin, and the like. The carbon sources that can be used include glucose and xylose mixed sugar as main carbon sources, and sugar and carbohydrates such as sucrose, lactose, fructose, maltose, starch and cellulose, soybean oil, sunflower oil, castor oil, Oils and fats such as oils and the like, fatty acids such as palmitic acid, stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid. These materials may be used individually or as a mixture. Nitrogen sources that may be used include inorganic sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, and ammonium nitrate; Amino acids such as glutamic acid, methionine and glutamine, and organic nitrogen sources such as peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolyzate, fish or their decomposition products, defatted soybean cake or decomposition products thereof . These nitrogen sources may be used alone or in combination. The medium may include potassium phosphate, potassium phosphate and the corresponding sodium-containing salts as a source. Potassium which may be used include potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts. As the inorganic compound, sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate and calcium carbonate may be used. Finally, in addition to these materials, essential growth materials such as amino acids and vitamins can be used. The preferred culture medium may be, for example, LB, YT or M9 medium, which is a medium for the growth of transformants.
본 발명에서 목적 물질인 아이소프레노이드는 HPLC 등을 통해 화합물을 분리하거나 당업계에 알려진 통상의 방법에 의해 화합물을 분리하여 수득할 수 있다.Isoprenoid, which is a target substance in the present invention, can be obtained by separating the compound through HPLC or the like or by separating the compound by a conventional method known in the art.
이하, 실시예를 통해 본 발명을 자세히 설명하도록 한다. 하기 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in detail by way of examples. It is to be understood that the following examples are illustrative only and are not intended to limit the scope of the invention in any way to the scope of the invention as defined by the appended claims. It will be obvious.
실시예Example 1. 인위적 세포 소기관 1. Anthropogenic organelle 조절능을Controllability 가진 재조합 효모 제조 Production of recombinant yeast
1.1. 세포 소기관 조절 관련 효소에 대한 유전자 조합을 포함하는 재조합 벡터의 제조 1.1. Preparation of recombinant vectors containing gene combinations for enzymes involved in cellular organelle regulation
세포 소기관 중 하나인 퍼옥시좀 (peroxisome)의 대사에 관여하는 효소인 퍼옥시좀 세포막 단백질 PEX34 (Peroxisomal membrane protein 34)의 코딩 유전자인 PEX34, 퍼옥시좀 세포막 단백질 PEX11 (Peroxisomal membrane protein 11)의 코딩 유전자인 PEX11, 및 퍼옥시좀 자기소화 관련 단백질 ATG36 (Peroxisome autophagy-related protein 36) 을 코딩하는 유전자인 ATG36을 중합효소 연쇄반응을 이용해 분리, 증폭시켰다. 또한 효모 내 세포 소기관의 조절에 따른 변화 유무를 확인하기 위해 사카로마이세스 세레비지에(Saccharomyces cerevisiae) 로부터 세포 소기관 중 하나인 퍼옥시좀의 세포막 단백질 중 하나인 3-케토아실-CoA 싸이올레이즈 (3-ketoacyl-CoA thiolase, POT1)을 중합효소 연쇄반응을 이용해 분리, 증폭시켰다. 상기 중합효소 연쇄반응에 사용된 정방향 및 역방향 프라이머는, 사카로마이세스 세레비지에의 퍼옥시좀 및 소포체 대사 관련 효소를 암호화하는 유전자의 염기서열 정보를 NCBI(National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/)에 있는 정보와 비교 분석한 결과를 토대로 제작하였으며, 각 유전자의 증폭에 사용된 정방향 및 역방향 프라이머의 염기서열 및 프라이머에 포함된 제한효소의 종류를 하기 표 1에 나타내었다.Cells oxy buffer, an enzyme involved in the metabolism of one of the peroxisome (peroxisome) of the scavenging some membrane protein PEX34 coding of the coding genes, PEX34, peroxisome membrane protein PEX11 (Peroxisomal membrane protein 11) of (Peroxisomal membrane protein 34) PEX11 gene, and peroxidase had little autolysis related protein ATG36 (peroxisome autophagy-related protein 36 ) to remove the gene encoding ATG36 using the polymerase chain reaction amplification. In order to confirm the changes in the organelles in the yeast cells, the Saccharomyces cerevisiae cerevisiae) were separated, amplified using the polymerase chain reaction of the 3-keto acyl -CoA thiol raised (3-ketoacyl-CoA thiolase, POT1) any of one of plasma membrane protein of some of the peroxide from the organelle. The forward and reverse primers used in the polymerase chain reaction can be obtained by sequencing the nucleotide sequence information of a gene encoding peroxisome and an endoplasmic reticulum-related enzyme to Saccharomyces cerevisiae using the NCBI (National Center for Biotechnology Information, http: /www.ncbi.nlm.nih.gov/), and the sequence of the forward and reverse primers used for the amplification of each gene and the type of the restriction enzyme contained in the primer Table 1 shows the results.
(Saccharomyces cerevisiae)SAKAROMAISE Serebijie
( Saccharomyces cerevisiae )
사카로마이세스 세레비지에의 염색체 DNA 주형 및 서열번호 1 및 2의 염기서열을 갖는 프라이머를 이용하여 PEX34 유전자를 증폭하였으며, 증폭된 유전자 단편을 BamHI 와 SalI으로 처리한 후 동일 효소로 절단된 pRS426-PGK1 벡터에 삽입하여 플라스미드 pRS426-PGK1 - PEX34를 제조하였다. The chromosomal DNA template of Saccharomyces cerevisiae and the primers having the nucleotide sequences of SEQ ID NOS: 1 and 2 were used to amplify the PEX34 gene. The amplified gene fragments were treated with BamHI and SalI, and then pRS426 - PGK1 vector to prepare plasmid pRS426- PGK1 - PEX34 .
이후, pRS426-PGK1 - PEX34 플라스미드의 유전자, PGK1 프로모터, 및 터미네이터를 포함한 DNA 주형을 SacI 및 KpnI 으로 처리하여 동일 효소로 절단된 플라스미드 pUC57_URA Blast에 삽입하여 플라스미드 pUC57_URA Blast-PGK1 - PEX34를 제조하였다. Thereafter, the pRS426- PGK1 - PEX34 plasmid gene, PGK1 Promoter and terminator was treated with Sac I and Kpn I and inserted into the plasmid pUC57_URA Blast cut with the same enzyme to prepare plasmid pUC57_URA Blast- PGK1 - PEX34 .
이후, pUC57_URA Blast 및 pUC57_URA Blast-PGK1 - PEX34 플라스미드의 영양 요구 인자 선택 지표 (Auxotroph selection marker) 유전자인 URA3 또는 프로모터 및 터미네이터를 포함한 각 유전자 모듈과 영양 요구 인자 선택 지표 (Auxotroph selection marker) 유전자인 URA3를 포함한 DNA 주형을 서열번호 3, 4, 5, 6, 7, 8, 9, 및 10의 염기서열을 갖는 프라이머를 이용하여 증폭하여 상동성 재조합(Homologous recombination)을 이용한 효모 형질 전환을 위한 ATG36 Del-URA3, PEX11Del-PGK1-PEX34-CYC1-URA3, 및 PGK1 - PEX34 - CYC1 - URA3 , 세포 소기관의 녹색 형광 단백질 지표 제작 형질 전환을 위한 POT1 - EGFP - CYC1 - URA3 카세트를 제조하였다.Since, pUC57_URA Blast and pUC57_URA Blast- PGK1 - PEX34 nutritional needs factors selected indicators (Auxotroph selection marker) gene or the URA3 gene promoter and each module and select indicators, including nutritional factors required terminator of the plasmid (Auxotroph selection marker) gene is URA3 Were amplified using a primer having the nucleotide sequence of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9 and 10 to obtain ATG36 Del- URA3, PEX11 Del- PGK1-PEX34- CYC1-URA3, and PGK1 - PEX34 - CYC1 - URA3, POT1 for green fluorescent protein, an indicator of cell organelles produced transgenic - EGFP - CYC1 - a URA3 cassette was prepared.
1.2 재조합 효모의 제조 및 세포 소기관 변화 검증1.2 Preparation of Recombinant Yeast and Verification of Cell Organelle Changes
상기 1.1에서 제조된 상동성 재조합 형질전환 카세트 PEX11Del-URA3, ATG36 Del-URA3, 및 PGK1 - PEX34 - CYC1 - URA3를 각각 야생형 효모 CEN PK2.1D에 도입시켜 형질전환하여 다음과 같은 표 2 의 재조합 효모를 제조하였다. The homologous recombinant transformation cassettes PEX11 Del- URA3 , ATG36 Del- URA3 , and PGK1 - PEX34 - CYC1 - URA3 prepared in the above 1.1 were introduced into wild-type yeast CEN PK2.1D, respectively, and transformed into the following recombinant Yeast was prepared.
상기 1.1에서 제조된 상동성 재조합 형질전환 카세트 POT1 - EGFP - CYC1 - URA3를 야생형 효모 Saccharomyces cerevisiae CEN PK2.1D, 재조합 효모 PX1, PX2, PX3, 및 PX4의 POT1 유전자의 C-말단에 종결 코돈을 제거하며 도입시키고 형질전환하여 CEN-POT1-EGFP, PX1-POT1 - EGFP, PX2-POT1 - EGFP, PX3-POT1 - EGFP, 및 PX4-POT1 - EGFP 재조합 효모를 제작하였다. The homologous recombinant transformation cassette POT1 - EGFP - CYC1 - URA3 prepared in 1.1 above was transformed into wild-type yeast Saccharomyces cerevisiae CEN PK2.1D, recombinant yeast PX1, PX2, PX3, and by removing the stop codon to the C- terminus of the POT1 gene and introduction of PX4 and transgenic CEN- POT1-EGFP, PX1- POT1 - EGFP, PX2- POT1 - EGFP , PX3- POT1 - EGFP , and PX4- POT1 - EGFP recombinant yeast were prepared.
형질전환된 각 재조합 효모의 단일 콜로니를 0.77 g/L 의 DO supplement-URA (Clontech)가 함유된 SD배지 (6.7 g/L 효소 질소 기반 아미노산 불포함 배지(yeast nitrogen base without amino acids), 및 20g/L 포도당(glucose)) 5㎖에 접종하여 30℃에서 24시간 진탕 배양하였으며, 얻어진 배양액 5㎖씩을 각각 100 ㎍/㎖의 DO supplement-URA를 함유한 SD배지 100㎖에 접종한 후 30℃에서 72시간 진탕 배양하였다. 이 후 24시간 간격으로 배양액 1㎖씩을 취하여 형광현미경을 이용해 세포 소기관의 변화 유무를 녹색 형광 단백질의 발현을 통해 확인하였다. 형광 현미경을 통해 확인된 재조합 효모 PX1, PX2, PX3 및 PX4 의 세포 소기관 변화 유무를 도 2에 나타내었다. A single colony of each transformed recombinant yeast was inoculated into SD medium (6.7 g / L yeast nitrogen base without amino acids) containing 0.77 g / L of DO supplement-URA (Clontech) and 20 g / L glucose) and incubated at 30 ° C for 24 hours with shaking. 5 ml of the obtained culture was inoculated into 100 ml SD medium containing 100 μg / ml DO supplement-URA, Time shake culture. Then, 1 ml of each culture was taken at 24 hour intervals, and the presence or absence of changes in the organelle was observed by fluorescence microscopy through the expression of green fluorescent protein. The presence or absence of changes in the organelle of the recombinant yeasts PX1, PX2, PX3 and PX4 identified by fluorescence microscopy is shown in Fig.
도 2에 나타낸 바와 같이, 재조합 효모 PX1, PX2, PX3 및 PX4에 해당하는 pex34 가 과발현되고, atg36 및/또는 pex11이 결실된 조합의 재조합 효모에서는 모두 녹색 형광 단백질 발현이 변화하였으며, 이를 통해 대조군 대비 모두 세포 소기관이 변화된 것을 확인하였다. 특히 pex30 또는 pex34 를 결실시킨 비교군의 경우 세포 소기관의 변화가 관찰되지 않았으며, pex34 를 결실시킨 실험군에서는 야생형과 유사한 정도의 형광만이 관찰되었다. 따라서, pex34 가 과발현되고, atg36 및/또는 pex11이 결실된 조합이 세포 소기관인 퍼옥시좀의 발현을 변화시킬 수 있는 최적의 조합임을 확인하였다. As shown in FIG. 2, the expression of green fluorescent protein was changed in the recombinant yeast in which recombinant yeast PX1, PX2, PX3 and PX4 corresponding to pex34 were overexpressed and atg36 and / or pex11 were deleted, All of the organelles were changed. In particular, no change was observed in the organelles of the pex30 or pex34 deletion group, whereas only the fluorescence of the wild type was observed in the pex34 deletion group. Therefore, it was confirmed that the combination of overexpression of pex34 and deletion of atg36 and / or pex11 is the optimal combination to change the expression of peroxisome, a cell organelle.
또한, 형질전환된 각 재조합 효모의 단일 콜로니를 0.77 g/L 의 DO supplement -URA (Clontech)가 함유된 SD배지 (6.7 g/L 효소 질소 기반 아미노산 불포함 배지(yeast nitrogen base without amino acids), 및 20g/L 포도당(glucose)) 5㎖에 접종하여 30℃에서 24시간 진탕 배양하였으며, 얻어진 배양액 5㎖씩을 각각 100 ㎍/㎖의 DO supplement-URA를 함유한 SD배지 100㎖에 접종한 후 30℃에서 72시간 진탕 배양하였다. 이 후 배양액 10㎖씩을 원심분리하여 균체를 얻은 후 이를 5㎖ 인산완충식염수 (Phosphate buffered saline, PBS)로 풀어 전자투과현미경 (Transmission electron microscopy, TEM) 분석을 위한 샘플을 준비하였다. TEM 분석을 위한 샘플 준비 및 분석은 서울대학교 농생명과학공동기기원 (NICEM)에서 진행되었다.A single colony of each transformed recombinant yeast was inoculated into SD medium (6.7 g / L yeast nitrogen base without amino acids) containing 0.77 g / L of DO supplement-UA (Clontech) 20 g / L glucose) and shake-cultured at 30 ° C for 24 hours. 5 ml of the resulting culture was inoculated into 100 ml of SD medium containing 100 μg / ml of DO supplement-URA, Lt; / RTI > for 72 hours. Then, 10 ml of each culture was centrifuged to obtain cells, which were then dissolved in 5 ml of phosphate buffered saline (PBS) to prepare samples for transmission electron microscopy (TEM) analysis. Sample preparation and analysis for TEM analysis were conducted by NICEM (National Institute of Agronomy Science, Seoul National University).
TEM 분석을 위해 인산완충식염수에 풀어진 균체를 원심분리하여 균체를 분리한 후, 개랑된 karnovsky의 고정화 용액(modified karnovsky's fixation solution, 2% paraformaldehyde & 2% glutaraldehyde in 0.05M sodium cacodylate buffer(pH 7.2))을 넣고 4시간동안 고정화를 진행하고, 0.05M 나트륨 카코딜산 완충액 (Sodium cacodylate buffer (pH7.2))로 3번 세척을 진행하였다. 세척 후 원심분리하여 상등액을 제거하고, 2% 오스뮴 사산화이질소 (Osmium tetroxide) 1ml과 0.1M 카코딜산 완충액 (Cacodylate buffer) 1ml을 첨가하여 2차 고정화를 진행했으며, 멸균수를 이용해 2회 세척을 진행하고 0.5% 우라닐 아세테이트 (Uranyl acetate)를 첨가하여 균체를 풀어준 후, 24시간 동안 엔-블록 (en-bloc)염색을 진행하였다. 다양한 농도의 에탄올 (30, 50, 70, 80, 90, 및 100%)로 농도를 순차적으로 높여가며 탈수소화반응 (Dehydration)을 3번 진행하고, 프로필렌 옥사이드 (Propylene oxide)를 첨가하여 10분 동안 반응을 진행한 후, 프로필렌 옥사이드 (Propylene oxide)와 스퍼 레진(spurr's resin, 4.1g ERL 4221, 1.43g D.E.R. 736, 5.9g NSA, 및 0.1g DMAE)으로 충진하여 1일동안 교반 반응을 진행하였다. 원심분리 후 균체를 분리하여 스퍼 레진 (spurr's resin, 4.1g ERL 4221, 1.43g D.E.R. 736, 5.9g NSA, 및 0.1g DMAE)으로 재충진 후, 70°C에서 건조시켜 EM UC7 초박편미세절단기 (Ultramicrotome)를 이용해 절단 박편을 준비하여 LIBRA 120 에너지여과 투과전자현미경 (Energy-filtering transmission electron microscopy, TEM)을 이용해 야생형 효모와 인위적 세포 소기관 조절능을 가진 재조합 효모의 세포 소기관의 변화 차이를 분석하였다. 그 결과를 도 3에 나타내었다. For the TEM analysis, the cells were separated by centrifugation in phosphate buffered saline, and then fixed with a modified Karnovsky's fixation solution (2% paraformaldehyde and 2% glutaraldehyde in 0.05M sodium cacodylate buffer (pH 7.2)). , Immobilized for 4 hours, and washed three times with 0.05M sodium cacodylate buffer (pH 7.2). After washing, the supernatant was removed by centrifugation. Secondary immobilization was performed by adding 1 ml of 2% Osmium tetroxide and 1 ml of 0.1 M Cacodylate buffer, followed by washing twice with sterilized water And the cells were loosened by the addition of 0.5% Uranyl acetate, followed by en-bloc staining for 24 hours. Dehydration was carried out three times with various concentrations of ethanol (30, 50, 70, 80, 90, and 100%) sequentially and propylene oxide was added for 10 minutes After the reaction was completed, propylene oxide and spurr's resin (4.1 g ERL 4221, 1.43 g DER 736, 5.9 g NSA, and 0.1 g DMAE) were charged and stirred for 1 day. After centrifugation, the cells were separated and re-packed with spurr's resin (4.1 g ERL 4221, 1.43 g DER 736, 5.9 g NSA, and 0.1 g DMAE) and dried at 70 ° C to obtain an EM UC7 ultra- Ultramicrotome was used to prepare cut slices and the differences in cell organelles of wild-type yeast and recombinant yeast with an artificial cell organellar regulating ability were analyzed using
도 3에 나타낸 바와 같이, 세포 소기관 중 하나인 퍼옥시좀 대사에 관여하는 효소인 퍼옥시좀 세포막 단백질 PEX34, 퍼옥시좀 세포막 단백질 PEX 11, 및 퍼옥시좀 자기소화 관련 단백질 ATG36을 암호화하는 유전자 PEX34 , PEX11 , 및 ATG36이 조절된 재조합 효모 PX1 내지 PX4 가 모두 퍼옥시좀의 수가 증가하고 크기가 증가하였음을 확인하였다. As shown in FIG. 3, the gene PEX34 encoding the peroxisome membrane protein PEX34, the peroxisome membrane protein PEX 11, and the peroxisome autolysis-related protein ATG36, enzymes involved in peroxisome metabolism, one of the cell organelles, , PEX11 , and ATG36 regulated recombinant yeast PX1 to PX4 increased the number and the size of peroxisome.
이를 통해, PEX34 , PEX11 , 및 ATG36의 조절을 통해, 세포소기관인 퍼옥시좀의 개수와 크기가 현저하게 증가된 인위적 세포 소기관 조절능을 가진 재조합 효모를 생산할 수 있음을 확인하였다. Thus, it was confirmed that the recombinant yeast having an artificial cellular organelles regulating ability that the number and size of the peroxidase, a cell organelle, was remarkably increased could be produced through the regulation of PEX34 , PEX11 and ATG36 .
실시예Example 2. 카로티노이드 2. Carotenoid 생산능Production capacity 향상 효모의 제조 Preparation of improved yeast
실시예 1을 통해 제조된 인위적 세포 소기관 조절능을 가진 재조합 효모를 이용하여, 유용물질인 아이소프레노이드 (isoprenoid) 중 카로티노이드를 생산할 수 있는지 여부를 확인하기 위하여 카로티노이드 생합성 대사 경로를 가지고 있지 않은 효모에 새로운 유전자 카세트를 도입하여 대표적인 C40 카로티노이드 물질 중 하나인 베타 카로틴을 생산하고 세포 소기관 조절을 통한 생산성을 비교하였다. To determine whether carotenoids in isoprenoid, which is a useful substance, could be produced by using recombinant yeast having an artificial cellular organelles regulating ability prepared in Example 1, yeasts that do not have a carotenoid biosynthetic pathway A new gene cassette was introduced to produce beta carotene, one of the representative C 40 carotenoids, and to compare the productivity through regulation of cell organelles.
2.1. 카로티노이드 생합성 관련 효소 유전자 조합을 포함하는 재조합 벡터의 제조2.1. Production of recombinant vector containing carotenoid biosynthesis-related enzyme gene combinations
사카로마이세스 세레비지에(Saccharomyces cerevisiae) 로부터 카로틴노이드 전구체 생합성에 관여하는 효소인 하이드록시메틸글루타릴-CoA 환원효소의 코딩 유전자인 HMG1의 유전자 활성 억제 부분을 일부 제거한 truncated HMG1 (tHMG1), 잔토필로마이시스 덴드로하우스(xanthophyllomyces dendrorhous)로부터 카로틴노이드 생합성에 관여하는 효소인 제라닐제라닐 피로인산 합성효소를 코딩하는 유전자인 CrtE, 파이토엔 합성 및 라이코펜 환상화효소를 코딩하는 유전자인 CrtYB, 및 파이토엔 불포화효소를 코딩하는 유전자인 CrtI를 중합효소 연쇄반응을 이용해 이를 분리, 증폭시켰다. 카로티노이드 중 하나인 베타카로틴 합성을 위한 MVA 및 MEP 경로를 포함하는 베타카로틴 생합성 대사 경로의 모식도를 도 4에 나타내었다. Mai Seth Serenity busy as Saccharomyces (Saccharomyces cerevisiae) gene encoding the carotene cannabinoid inhibition portion of the HMG1 gene of the enzyme hydroxymethyl glutaryl -CoA reductase involved in the biosynthesis of precursor removed from the part truncated HMG1 (tHMG1), xanthophylls Roman Isis dendeuro house (xanthophyllomyces CrtE , a gene encoding a geranyl geranyl pyrophosphate synthase, an enzyme involved in carotenoid biosynthesis from dendrorhous , CrtYB , a gene encoding phytoene synthase and lycopene cyclic enzyme, and a gene encoding phytoene- unsaturated enzyme Were isolated and amplified by polymerase chain reaction. A schematic diagram of the beta carotene biosynthetic pathway including MVA and MEP pathway for synthesis of beta carotene, one of the carotenoids, is shown in FIG.
상기 중합효소 연쇄반응에 사용된 정방향 및 역방향 프라이머는, 사카로마이세스 세레비지에, 잔토필로마이시스 덴드로하우스의 카로틴노이드 및 전구체 생합성 경로 관련 효소를 암호화하는 유전자의 염기서열 정보를 NCBI(National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/)에 있는 정보와 비교 분석한 결과를 토대로 제작하였으며, 각 유전자의 증폭에 사용된 정방향 및 역방향 프라이머의 염기서열 및 프라이머에 포함된 제한효소의 종류를 하기 표 3에 나타내었다.The forward and reverse primers used for the polymerase chain reaction were obtained by sequencing the nucleotide sequence information of the gene encoding Saccharomyces cerevisiae, the carotenoid of Zanthophylloma isolis dendrobians, and the enzyme involved in the precursor biosynthesis pathway with the NCBI for Biotechnology Information, http://www.ncbi.nlm.nih.gov/), and included in the base sequence and primer of the forward and reverse primers used for the amplification of each gene The types of restriction enzymes are shown in Table 3 below.
(xanthophyllomyces dendrorhous)Zontopil Roma Isis Dendro House
( xanthophyllomyces dendrorhous )
(Saccharomyces cerevisiae)SAKAROMAISE Serebijie
( Saccharomyces cerevisiae )
-tHMG1YIplac128-GPD
-tHMG1
(xanthophyllomyces dendrorhous)Zontopil Roma Isis Dendro House
( xanthophyllomyces dendrorhous )
먼저, 사카로마이세스 세레비지에의 유전자 정보를 바탕으로 합성된 유전자의 DNA 주형 및 서열번호 11 및 12의 염기서열을 갖는 프라이머를 이용하여 tHMG1 유전자를 증폭하였으며, 증폭된 유전자 단편을 NotI 과 SpeI으로 처리한 후 동일 효소로 절단된 pRS424-GPD 벡터에 삽입하여 플라스미드 pRS424-GPD - tHMG1을 제조하였다. First, the tHMG1 gene was amplified using the DNA template of the gene synthesized based on the gene information on Saccharomyces cerevisiae and a primer having the nucleotide sequence of SEQ ID NOS: 11 and 12. The amplified gene fragment was amplified by Not I After treatment with Spe I, pRS424- GPD digested with the same enzyme Vector to prepare plasmid pRS424- GPD - tHMG1 .
이후, pRS424-GPD - tHMG1 플라스미드의 유전자, GPD 프로모터, 및 터미네이터를 포함한 DNA 주형을 서열번호 13 및 14의 염기서열을 갖는 프라이머를 이용하여 증폭한 후, 이를 PstI 과 SalI으로 처리하여 동일 효소로 절단된 플라스미드 YIplac128에 삽입하여 플라스미드 YIplac128-GPD - tHMG1을 제조하였다. Thereafter, the gene of pRS424- GPD - tHMG1 plasmid, GPD Promoter, and terminator was amplified using primers having the nucleotide sequences of SEQ ID NOS: 13 and 14, and then treated with Pst I and Sal I and inserted into plasmid YIplac128 digested with the same enzyme to obtain plasmid YIplac128- GPD - tHMG1 .
이후, YIplac126-GPD - tHMG1 플라스미드의 프로모터 및 터미네이터를 포함한 각 유전자 모듈과 영양 요구 인자 선택 지표 (Auxotroph selection marker) 유전자인 LEU2 를 포함한 DNA 주형을 서열번호 15 및 16의 염기서열을 갖는 프라이머를 이용하여 증폭하여 상동성 재조합을 이용한 효모 형질 전환을 위한 GPD - tHMG1 -CYC1-LEU2 카세트를 제조하였다.Thereafter, a DNA template containing each gene module including a promoter and terminator of YIplac126- GPD - tHMG1 plasmid and LEU2 gene as an auxotroph selection marker gene was amplified using primers having the nucleotide sequences of SEQ ID NOs: 15 and 16 To produce GPD - tHMG1 -CYC1-LEU2 cassettes for yeast transformation using homologous recombination.
또한, 잔토필로마이세스 덴드로하우스의 전령 RNA를 주형으로 하여 역전사 효소 반응을 통해 cDNA를 합성하였으며, 합성된 cDNA 주형 및 서열번호 17, 18, 19, 20, 21 및 22의 염기서열을 갖는 프라이머를 이용하여 crtE , crtYB , crtI 각각의 유전자를 증폭하고, 증폭된 유전자 단편을 제한효소 SpeI 과 XmaI, BamHI 과 SalI, 또는 BamHI과 SalI으로 처리하였다. 이후 동일 효소로 절단된 pRS426-TEF1, pRS423-PGK1, 및 pRS424-PGK1 벡터에 삽입하여 플라스미드 pRS426-TEF1 - crtE, pRS423-PGK1-crtYB, 및 pRS424-PGK1 - crtI를 제조하였다.CDNA was synthesized by reverse transcriptase using as a template the messenger RNA of Zanthorpylomyces dendrovus as a template. The cDNA template and the primers having the nucleotide sequences of SEQ ID NOs: 17, 18, 19, 20, 21 and 22 Using crtE , crtYB , crtI Each gene was amplified and the amplified gene fragment was treated with restriction enzymes Spe I and Xma I, Bam HI and Sal I, or Bam HI and Sal I. After inserted into the pRS426- TEF1, PGK1 pRS423-, and pRS424- PGK1 vector digested with the same restriction enzyme plasmid pRS426- TEF1 - was prepared crtI - crtE, pRS423- PGK1-crtYB , and pRS424- PGK1.
상기 유전자들을 염색체 상에 도입시키기 위하여 CRISPR-Cas9(Clustered Regularly Interspaced Short Palindromic Repeats-Cas9) 방법을 이용해 CrtE , CrtYB, 및 CrtI를 효모의 ypl062w , ROX1 , 및 yjl064w에 도입하였다. 형질전환을 위한 ypl062w , ROX1 , 및 yjl064w 염기서열을 인식하는 sgRNA 발현 벡터의 제작을 위해 pSRNR52-sgTEF1 벡터를 주형가닥으로 하여 EcoRI 효소의 인식부위가 포함된 서열번호 23의 염기서열을 갖는 프라이머와 PAM 서열이 포함된 서열번호 24, 27, 및 29의 염기서열을 갖는 프라이머를 이용하여 첫 번째 절편을 증폭하고, 5'-NGG-3'를 포함한 PAM 서열이 포함된 서열번호 25, 28, 및 30의 염기서열을 갖는 프라이머와 KpnI 효소의 인식부위가 포함된 서열번호 26의 염기서열을 갖는 프라이머를 이용하여 두 번째 절편을 증폭하였다. 이 두 절편을 주형 가닥으로 하여 EcoRI 효소의 인식부위가 포함된 서열번호 23의 염기서열을 갖는 프라이머와 KpnI 효소의 인식부위가 포함된 서열번호 26의 염기서열을 갖는 프라이머를 이용한 overlap extension PCR을 진행하여 sgRNA 서열이 포함된 DNA 절편을 확보하였다. 이 DNA 절편을 KpnI 과 EcoRI 효소로 처리한 후, 동일 효소로 처리된 pSNR52-sgTEF1 벡터에 삽입하여 CrtE, CrtYB , 및 CrtI를 도입할 ypl062w , ROX1 , 및 yjl064w 부위를 인식하는 pSNR52-sgypl062w, SNR52-sgROX1, SNR52-sgyjl064w 벡터를 제조하였다.In order to introduce the gene on a chromosome-Cas9 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats-Cas9) using the method CrtE, CrtYB, CrtI and of the yeast ypl062w, ROX1, and on yjl064w Respectively. Ypl062w , ROX1 , and & lt ; RTI ID = 0.0 & gt ; For the construction of the sgRNA expression vector recognizing the base sequence of yjl064w, the pSRNR52-sg TEF1 vector was used as a template strand, and a primer having the nucleotide sequence of SEQ ID NO: 23 containing the Eco RI enzyme recognition site and a primer having the PAM sequence , 27, and 29 were used to amplify the first fragment, and primers having the nucleotide sequences of SEQ ID NOS: 25, 28, and 30 containing the PAM sequence containing 5'-NGG-3 ' The second fragment was amplified using a primer having the nucleotide sequence of SEQ ID NO: 26 containing the recognition site of the Kpn I enzyme. Using these two fragments as a template strand, a primer having the nucleotide sequence of SEQ ID NO: 23 containing the Eco RI enzyme recognition site and an extension extension PCR using the primer having the nucleotide sequence of SEQ ID NO: 26 containing the recognition site of the Kpn I enzyme To obtain a DNA fragment containing the sgRNA sequence. The DNA fragment of Kpn I and Eco RI and then treated with the enzyme, and then inserted into the treated with the same restriction enzyme pSNR52-sg TEF1 vector to introduce CrtE, CrtYB, and CrtI ypl062w, ROX1, and pSNR52 -sg ypl062w , SNR52-sg ROX1 and SNR52-sg yjl064w vectors recognizing the yjl064w site were prepared.
이후, pRS426-TEF1 - CrtE, pRS423-PGK1 - CrtYB, 및 pRS424-PGK1 - CrtI 플라스미드의 프로모터 및 터미네이터를 포함한 각 유전자 모듈을 포함한 DNA 주형을 서열번호 31, 32, 33, 34, 35, 및 36의 염기서열을 갖는 프라이머를 이용하여 증폭하여 CRISPR-Cas9 방법을 이용한 효모 형질 전환을 위한 TEF1 - CrtE - CYC1 , PGK1 - CrtYB -CYC1, 및 PGK1 - CrtI - ADH1 카세트를 제조하였다. The DNA template containing each gene module including the promoter and terminator of pRS426- TEF1 - CrtE , pRS423- PGK1 - CrtYB , and pRS424- PGK1 - CrtI plasmid was designated SEQ ID NOS: 31, 32, 33, 34, 35, and 36 PCR primers were used to prepare TEF1 - CrtE - CYC1 , PGK1 - CrtYB - CYC1 , and PGK1 - CrtI - ADH1 cassettes for yeast transformation using the CRISPR - Cas9 method .
2.2 인위적 세포 소기관 2.2 Anthropogenic organelles 조절능을Controllability 가진 재조합 효모를 이용한 카로티노이드 생산성 향상 비교 Comparison of Carotenoid Productivity Improvement Using Recombinant Yeast
상기 2.1 에서 제조된 형질전환 카세트 GPD - tHMG1 - CYC1을 야생형 효모와 실시예 1에서 제작한 인위적 세포 소기관 조절능을 가진 재조합 효모 PX 1에 도입시켜 형질전환 시켰으며, 이후 상기 2.1 에서 제조된 형질전환 카세트 TEF1 - CrtE -CYC1, PGK1 - CrtYB - CYC1 , 및 PGK1 - CrtI - ADH2, Cas9 발현 벡터인 Cas9-NAT(Addgene, Plasmid #64329) 벡터, 및 ypl062w , ROX1 , yjl064w 부위를 각각 인식하는 sgRNA 발현 벡터인 pSNR52-sg 벡터를 야생형 효모와 실시예 1에서 제작한 인위적 세포 소기관 조절능을 가진 재조합 효모 중 퍼옥시좀 자기소화 관련 단백질 ATG36 (ATG36)을 제거한 효모 PX1 에 도입시켰다. 형질전환된 각각의 재조합 효모를 CEN-βCN(대조군)과 PX1-βCN 으로 명명하였다. The transformant cassette GPD - tHMG1 - CYC1 prepared in the above 2.1 was transformed into wild-type yeast and
형질전환된 각 재조합 효모의 단일 콜로니를 YPD배지 (10g/L 효소추출물(yeast extract), 20g/L 펩톤 (peptone), 및 20g/L 포도당(glucose)) 5㎖에 접종하여 30℃에서 24시간 진탕 배양하였으며, 얻어진 배양액 5㎖씩을 각각 YPD배지 (10g/L 효소추출물(yeast extract), 20g/L 펩톤 (peptone), 및 20g/L 포도당(glucose)) 50㎖에 접종한 후 30℃에서 144시간 진탕 배양하였다. 이 후 배양액 1㎖씩을 취하여 분광광도계를 이용해 600 nm의 파장에서 흡광도를 측정한 후 희석배수를 곱하여 균체량을 확인하였다. 또한, 배양된 각 50㎖ 배지를 원심분리 하여 균체를 얻은 후 이를 5㎖ 100% 아세톤(acetone)으로 풀어 발현된 카로틴노이드를 추출하고, 10㎖ 헥산(hexane)과 물(H2O)로 카로틴노이드 층을 나눠 카로틴노이드를 분리 시켰다. 분리된 카로틴노이드를 유리시험관으로 옮긴 후 고압건조기를 이용해 30분간 건조 시키고, 건조된 카로틴노이드 추출물을 1㎖ 에틸아세테이트로 녹인 다음 20㎕의 추출물을 고압액체크로마토그래피(HPLC) 광다이오드배열 검출기(DAD)를 이용해 베타카로틴을 측정하였다. 측정값을 검량선을 통해 얻은 방정식에 대입하였고, 희석 배수를 계산하여 베타카로틴양을 계산하였다. 이때, 검량선 작성을 위해서 표준 베타카로틴(Sigma aldrich)을 구입하여 에틸아세테이트에 용해시킨 후 각각 다른 농도로 에틸아세테이트에 희석하여 고압액체크로마토그래피 광다이오드배열 검출기를 이용해 베타카로틴 양을 측정하고 이를 이용해 표준 검량선을 작성하였다. 수행한 고압액체크로마토그래피의 조건은 하기와 같다. A single colony of each transformed recombinant yeast was inoculated in 5 ml of YPD medium (10 g / L yeast extract, 20 g / L peptone, and 20 g / L glucose) Each 5 ml of the obtained culture was inoculated into 50 ml of YPD medium (10 g / L yeast extract, 20 g / L peptone, and 20 g / L glucose) Time shake culture. After that, 1 ml of each culture was taken and the absorbance was measured at a wavelength of 600 nm using a spectrophotometer, and the amount of the cells was determined by multiplying by the dilution factor. The cultured 50-ml medium was centrifuged to obtain cells, which were then extracted with 5 ml of 100% acetone to extract the expressed carotenoids. Carotenoids were extracted with 10 ml of hexane and water (H 2 O) The nodal layer was split to separate the carotenoids. The separated carotenoids were transferred to a glass test tube and dried in a high pressure dryer for 30 minutes. The dried carotenoid extract was dissolved in 1 ml of ethyl acetate, and 20 μl of the extract was subjected to high pressure liquid chromatography (HPLC) photodiode array detector (DAD ) Was used to measure beta-carotene. The measured value was substituted into the equation obtained through the calibration curve, and the amount of beta carotene was calculated by calculating the dilution factor. For the calibration curve, standard beta-carotene (Sigma aldrich) was purchased and dissolved in ethyl acetate. The concentration of beta-carotene was measured using a high-pressure liquid chromatography photodiode array detector and diluted with ethyl acetate at different concentrations. A calibration curve was prepared. The conditions of the high pressure liquid chromatography performed are as follows.
- 고압액체크로마토그래피: 시료주입장치(auto-sampler)가 장착된 에이질런트 테크놀로지 1200 시리즈 (Agilent Technologies 1200 series) 모델- High Pressure Liquid Chromatography: Agilent Technologies 1200 series model with auto-sampler
- 광다이오드배열 검출기: 에이질런트 테크놀로지 1200 시리즈 (Agilent Technologies 1200 series) 모델- Photodiode array detector: Agilent Technologies 1200 series model
- 컬럼: Agilent Zorbax XDB-C18 (4.6 × 150 mm, 5-micron) Column: Agilent Zorbax XDB-C18 (4.6 x 150 mm, 5-micron)
- Mobile phase: Acetonitrile: 80/ Methanol: 15/ Isoprepanol: 5 (v/v %)- Mobile phase: Acetonitrile: 80 / Methanol: 15 / Isoprepanol: 5 (v / v%)
- 속도: 1.0 ㎖/분- Rate: 1.0 ml / min
- Column 온도: 35℃- Column temperature: 35 ℃
- 측정기: DAD (Diode array detector)- Measuring device: DAD (Diode array detector)
- 시료주입량: 20㎕- Sample injection amount: 20 μl
- 검출: spectrometry 방식 (190nm ~ 900nm)- Detection: spectrometry method (190nm ~ 900nm)
상기 방법으로 확인된, 인위적 세포 소기관 조절을 통해 향상된 베타카로틴의 생산능을 가진 재조합 효모의 균체량 및 각 베타카로틴의 생산량을 하기 표 4 및 도 5에 나타내었다.The amount of the recombinant yeast having the ability to produce beta carotene and the amount of each beta carotene produced through the artificial cell organellar regulation, confirmed by the above method, And 5.
(OD600)Maximal device
(OD600)
절대정량값 (mg/L)Beta-carotene
Absolute quantitative value (mg / L)
상기 표 4 및 도 5에 나타낸 바와 같이, 실시예 1의 인위적 세포 소기관 조절능을 가진 재조합 효모에 카로틴노이드 중 하나인 베타카로틴을 생산하는 효소인 개량된 하이드록시메틸글루타릴-CoA 환원효소, 제라닐제라닐 피로인산 합성효소, 파이토엔 합성 및 라이코펜 환상화효소, 및 파이토엔 불포화효소를 암호화하는 유전자 조합이 발현되는 형질전환 카세트 GPD - tHMG1 - CYC1, TEF1 - CrtE - CYC1 , PGK1 -CrtYB-CYC1, 및 PGK1 - CrtI - ADH2를 도입하는 경우, 동일한 형질전환 카세트를 도입한 야생형 효모와 비교하여, 최대 성장치는 다소 감소하였으나 베타 카로틴의 절대 생산량은 증가하는 것을 확인하였다. 도 5A 에 나타낸 바와 같이, 세포 성장치가 감소하더라도 균체 회수 시 야생형과 크게 차이나지 않았으며, 야생형 대비 베타카로틴의 증가로 인해 짙은 주황색을 나타내었다. As shown in Table 4 and FIG. 5, the recombinant yeast having an artificial cellular organotypic regulation ability of Example 1, an improved hydroxymethylglutaryl-CoA reductase, an enzyme that produces beta carotene, which is one of the carotenoids, geranyl geranyl pyrophosphate synthase, payito yen synthetic lycopene and cyclic enzymes, and payito yen transgenic cassettes that this DNA, coding for the enzyme expression unsaturated GPD - tHMG1 - CYC1, TEF1 - CrtE - CYC1, PGK1 -CrtYB- CYC1, and PGK1 - CrtI - When introducing ADH2, as compared with the introduction of the same transformation cassette wild-type yeast, although slightly reduced value up to an absolute growth production of beta-carotene was confirmed to increase. As shown in FIG. 5A, even when the cell growth value was decreased, it was not significantly different from the wild type at the time of recovery of the cells, and showed a deep orange color due to the increase of beta-carotene compared to the wild type.
도 5B 에 나타낸 바와 같이, 카로티노이드가 미생물 내 과발현되는 경우 카로티노이드가 세포막에 축적되어 세포 성장이 저해되는 문제가 발생하기 때문에 인위적 세포 소기관 조절을 통해 향상된 베타카로틴의 생산능을 가진 재조합 효모의 최대 성장치는 다소 낮아졌으나, 도 5C에 나타낸 바와 같이 베타 카로틴의 생산량은 오히려 증대하였다. 구체적으로 베타카로틴 생산량이 배양 부피 기준 최대 130% 및 단위 세포 기준 최대 165%까지 더욱 증가하였으며, 이를 통해 인위적 세포 소기관 조절능을 가진 재조합 효모를 이용하는 경우, 높은 카로틴노이드 생산성을 나타냄을 확인하였다.As shown in FIG. 5B, when the carotenoid is over-expressed in the microorganism, the carotenoid is accumulated in the cell membrane and the cell growth is inhibited. Therefore, the maximum growth value of the recombinant yeast having the ability to produce beta carotene improved through artificial cellular organelle regulation But the production of beta-carotene was rather increased as shown in Fig. 5C. Specifically, the production of beta-carotene was further increased up to 130% based on the culture volume and up to 165% based on the unit cell. Thus, it was confirmed that the recombinant yeast having an artificial cellular organelle control ability exhibited high carotenoid productivity.
실시예Example 4. 4. 지베렐린Gibberellin 대사물질 Metabolite 생산능Production capacity 향상 효모의 제조 Preparation of improved yeast
실시예 1을 통해 제조된 인위적 세포 소기관 조절능을 가진 재조합 효모를 이용하여, 유용물질인 아이소프레노이드 (isoprenoid) 중 지베렐린 주요 대사물질인 카우린(Kaurene)을 생산할 수 있는지 여부를 확인하기 위하여 지레렐린 생합성 대사 경로를 가지고 있지 않은 효모에 새로운 유전자 카세트를 도입하여 카우린을 생산하고 세포 소기관 조절을 통한 생산성을 비교하였다. To confirm whether kaurene, a major metabolite of gibberellin in isoprenoid, which is a useful substance, can be produced using recombinant yeast having an artificial cellular organelle control ability prepared in Example 1, A novel gene cassette was introduced into yeast that did not have a pathway for the production of cholines, and productivity was regulated through regulation of cell organelles.
4.1 4.1 지베렐린Gibberellin 대사물질 생합성 관련 효소 유전자 조합을 포함하는 재조합 벡터의 제조 Preparation of a recombinant vector containing a combination of enzyme genes related to metabolic biosynthesis
사카로마이세스 세레비지에(Saccharomyces cerevisiae) 로부터 지베렐린 전구체 생합성에 관여하는 효소인 하이드록시메틸글루타릴-CoA 환원효소의 코딩 유전자인 HMG1의 유전자 활성 억제 부분을 일부 제거한 truncated HMG1 (tHMG1), 잔토필로마이시스 덴드로하우스(xanthophyllomyces dendrorhous)로부터 지베렐린 대사물질 생합성에 관여하는 효소인 제라닐제라닐 피로인산 합성효소를 코딩하는 유전자인 CrtE, 푸자리움 푸지쿠로이 (Fusarium fujikuroi)로부터 지베렐린 대사물질 생합성에 관여하는 효소 중 코파릴 피로인산 및 카우린 합성효소를 코딩하는 유전자인 CDPS /KS를 분리, 증폭시켰다. 지베렐린 대사물질 중 하나인 카우린 생합성을 위한 MVA 및 MEP 경로를 포함하는 대사 경로의 모식도를 도 6에 나타내었다.Mai Seth Serenity busy as Saccharomyces (Saccharomyces cerevisiae) gene encoding the active portion of the suppressing gene HMG1 the enzyme hydroxymethyl glutaryl -CoA reductase enzymes involved in gibberellin biosynthesis precursor removed from the part truncated HMG1 (tHMG1), xanthophylls Roman Isis dendeuro house (xanthophyllomyces dendrorhous ), a gene encoding a geranyl geranyl pyrophosphate synthase, which is an enzyme involved in biosynthesis of gibberellin metabolite, CrtE , Fusarium fujium fujikuroi ) was isolated and amplified from CDPS / KS , which is a gene encoding coarylpyrophosphate and kaurin synthase, among enzymes involved in the biosynthesis of gibberellin metabolites. A schematic diagram of the metabolic pathway including MVA and MEP pathway for kaurin biosynthesis, one of the gibberellin metabolites, is shown in FIG.
상기 중합효소 연쇄반응에 사용된 정방향 및 역방향 프라이머는, 사카로마이세스 세레비지에, 잔토필로마이시스 덴드로하우스, 및 푸자리움 푸지쿠로이의 지베렐린 및 전구체 생합성 경로 관련 효소를 암호화하는 유전자의 염기서열 정보를 NCBI(National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/)에 있는 정보와 비교 분석한 결과를 토대로 제작하였으며, 각 유전자의 증폭에 사용된 정방향 및 역방향 프라이머의 염기서열 및 프라이머에 포함된 제한효소의 종류를 하기 표 5에 나타내었다.The forward and reverse primers used for the polymerase chain reaction were prepared by sequencing the nucleotide sequences of the genes encoding Saccharomyces cerevisiae, Zonthorphemaeisstendendorhaus, and the gibberellin and the precursor biosynthetic pathway-related enzyme of Fusarium fujicullo The information was compiled from the results of comparative analysis with the information in the NCBI (National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/), and the forward and reverse primers The nucleotide sequences and types of restriction enzymes contained in the primers are shown in Table 5 below.
(Fusarium fujikuroi)Fujarium Fujikuroi
( Fusarium fujikuroi )
(Saccharomyces cerevisiae)SAKAROMAISE Serebijie
( Saccharomyces cerevisiae )
-tHMG1YIplac128-GPD
-tHMG1
(xanthophyllomyces dendrorhous)Zontopil Roma Isis Dendro House
( xanthophyllomyces dendrorhous )
(Fusarium fujikuroi)Fujarium Fujikuroi
( Fusarium fujikuroi )
먼저, 사카로마이세스 세레비지에의 유전자 정보를 바탕으로 합성된 유전자의 DNA 주형 및 서열번호 11, 및 12의 염기서열을 갖는 프라이머를 이용하여 tHMG1 유전자를 증폭하였으며, 증폭된 유전자 단편을 NotI 과 SpeI으로 처리한 후 동일 효소로 절단된 pRS424-GPD 벡터에 삽입하여 플라스미드 pRS424-GPD - tHMG1을 제조하였다. First, the tHMG1 gene was amplified using a DNA template of the gene synthesized based on the genomic information of Saccharomyces cerevisiae and a primer having a nucleotide sequence of SEQ ID NOs: 11 and 12. The amplified gene fragment was amplified by Not I And Spe I, and then digested with the same enzyme, pRS424- GPD Vector to prepare plasmid pRS424- GPD - tHMG1 .
이후, pRS424-GPD - tHMG1 플라스미드의 유전자, GPD 프로모터, 및 터미네이터를 포함한 DNA 주형을 서열번호 13 및 14의 염기서열을 갖는 프라이머를 이용하여 증폭한 후, 이를 PstI 과 SalI으로 처리하여 동일 효소로 절단된 플라스미드 YIplac128에 삽입하여 플라스미드 YIplac128-GPD - tHMG1을 제조하였다. Thereafter, the gene of pRS424- GPD - tHMG1 plasmid, GPD Promoter, and terminator was amplified using primers having the nucleotide sequences of SEQ ID NOS: 13 and 14, and then treated with Pst I and Sal I and inserted into plasmid YIplac128 digested with the same enzyme to obtain plasmid YIplac128- GPD - tHMG1 .
이후, YIplac126-GPD - tHMG1 플라스미드의 프로모터 및 터미네이터를 포함한 각 유전자 모듈과 영양 요구 인자 선택 지표 (Auxotroph selection marker) 유전자인 LEU2 를 포함한 DNA 주형을 서열번호 15 및 16의 염기서열을 갖는 프라이머를 이용하여 증폭하여 상동성 재조합을 이용한 효모 형질 전환을 위한 GPD - tHMG1 -CYC1-LEU2 카세트를 제조하였다.Thereafter, a DNA template containing each gene module including a promoter and terminator of YIplac126- GPD - tHMG1 plasmid and LEU2 gene as an auxotroph selection marker gene was amplified using primers having the nucleotide sequences of SEQ ID NOs: 15 and 16 To produce GPD - tHMG1 -CYC1-LEU2 cassettes for yeast transformation using homologous recombination.
또한, 잔토필로마이세스 덴드로하우스 및 푸자리움 푸지쿠로이의 전령 RNA를 주형으로하여 역전사 효소 반응을 통해 cDNA를 합성하였으며, 합성된 cDNA 주형 및 서열번호: 17, 18, 37 및 38의 염기서열을 갖는 프라이머를 이용하여 crtE 및 CDPS/KS 각각의 유전자를 증폭하였다. 증폭된 유전자 단편을 제한효소 SpeI과 XmaI 및 SpeI 과 XhoI으로 처리한 후 동일 효소로 절단된 pRS426-TEF1 및 pRS426-PGK1 벡터에 삽입하여 플라스미드 pRS426-TEF1 - crtE 및 pRS426-PGK1 - CDPS /KS를 제조하였다.In addition, cDNA was synthesized through reverse transcriptase reaction using messenger RNA of Zanthorpylomyces staine dendrohaeus and Fusarium pujicullo as a template, and the cDNA template and the nucleotide sequence of SEQ ID NOs: 17, 18, 37 and 38 RTI ID = 0.0 > rtE < / RTI > And CDPS / KS genes were amplified. The amplified gene fragments were treated with restriction enzymes Spe I, Xma I, Spe I and Xho I and inserted into the pRS426- TEF1 and pRS426- PGK1 vectors digested with the same enzymes to obtain plasmids pRS426- TEF1 - crtE and pRS426- PGK1 - CDPS / KS .
이후, CRISPR-Cas9 방법을 이용해 CrtE 및 CDPS /KS를 효모의 ypl062w 및 ROX1에 도입하였으며, 형질전환을 위한 ypl062w 및 ROX1 염기서열을 인식하는 sgRNA 발현 벡터의 제작을 위해 pSRNR52-sgTEF1 벡터를 주형가닥으로 하여 EcoRI 효소의 인식부위가 포함된 서열번호 23의 염기서열을 갖는 프라이머와 PAM 서열이 포함된 서열번호 24 및 27의 염기서열을 갖는 프라이머를 이용하여 첫 번째 절편을 증폭하였다. 5'-NGG-3'를 포함한 PAM 서열이 포함된 서열번호 25 및 28의 염기서열을 갖는 프라이머와 KpnI 효소의 인식부위가 포함된 서열번호 26의 염기서열을 갖는 프라이머를 이용하여 두 번째 절편을 증폭하였다. 이 두 절편을 주형 가닥으로 하여 EcoRI 효소의 인식부위가 포함된 서열번호 23의 염기서열을 갖는 프라이머와 KpnI 효소의 인식부위가 포함된 서열번호 26의 염기서열을 갖는 프라이머를 이용한 overlap extension PCR을 진행하여 sgRNA 서열이 포함된 DNA 절편을 확보하였다. 이 DNA 절편을 KpnI 및 EcoRI 효소로 처리한 후, 동일 효소로 처리된 pSNR52-sgTEF1 벡터에 삽입하여 CrtE 및 CDPS /KS를 도입할 ypl062w 및 ROX1부위를 인식하는 pSNR52-sgypl062w 및 SNR52-sgROX1 벡터를 제조하였다.Then, CrtE and CDPS / KS were incubated with yeast's yepl062w And ROX1 YPl062W for transfection. And To construct an sgRNA expression vector recognizing the ROX1 nucleotide sequence, a pSRNR52-sg TEF1 vector was used as a template strand, and a primer having the nucleotide sequence of SEQ ID NO: 23 containing the recognition region of the Eco RI enzyme and a primer having the nucleotide sequence of SEQ ID NO: And 27 were used to amplify the first fragment. A primer having the nucleotide sequence of SEQ ID NOs: 25 and 28 containing the PAM sequence containing 5'-NGG-3 'and a primer having the nucleotide sequence of SEQ ID NO: 26 including the recognition site of the Kpn I enzyme were used for the second fragment Lt; / RTI > Using these two fragments as a template strand, a primer having the nucleotide sequence of SEQ ID NO: 23 containing the Eco RI enzyme recognition site and an extension extension PCR using the primer having the nucleotide sequence of SEQ ID NO: 26 containing the recognition site of the Kpn I enzyme To obtain a DNA fragment containing the sgRNA sequence. After treating this DNA fragment with Kpn I and Eco RI enzymes, and then inserted into the treated with the same restriction enzyme pSNR52-sg TEF1 ypl062w vector to introduce and CrtE CDPS / KS And PSNR52 -sg ypl062w and SNR52-sg ROX1 vectors recognizing the ROX1 region were prepared.
이후, pRS426-TEF1 - CrtE 및 pRS426-TEF1 - CDPS /KS 플라스미드의 프로모터 및 터미네이터를 포함한 각 유전자 모듈을 포함한 DNA 주형을 서열번호 31, 32, 33, 및 34의 염기서열을 갖는 프라이머를 이용하여 증폭하여 CRISPR-Cas9 방법을 이용한 효모 형질 전환을 위한 TEF1 - CrtE - CYC1 및 PGK1 - CDPS /KS- TEF2 카세트를 제조하였다. The DNA template containing each gene module including the promoter and terminator of pRS426 - TEF1 - CrtE and pRS426- TEF1 - CDPS / KS plasmid was amplified using primers having the nucleotide sequences of SEQ ID NOS: 31, 32, 33 and 34 TEF1 - CrtE - CYC1 for yeast transformation using the CRISPR-Cas9 method And PGK1 - CDPS / KS- TEF2 cassette.
4.2 인위적 세포 소기관 4.2 Anthropogenic organelles 조절능을Controllability 가진 재조합 효모를 이용한 With recombinant yeast 카우린Kaurin 생산성 향상 비교 Productivity improvement comparison
상기 3.1 에서 제조된 형질전환 카세트 GPD - tHMG1 - CYC1을 야생형 효모와 실시예 1에서 제작한 인위적 세포 소기관 조절능을 가진 재조합 효모 PX 1에 도입시켜 형질전환 시켰으며, 이후 상기 3.1 에서 제조된 형질전환 카세트 TEF1 - CrtE -CYC1 및 PGK1 - CDPS /KS- TEF2, Cas9 발현 벡터인 Cas9-NAT(Addgene, Plasmid #64329) 벡터, 및 ypl062w 및 ROX1 부위를 각각 인식하는 sgRNA 발현 벡터인 pSNR52-sgypl062w 및 SNR52-sgROX1 벡터를 야생형 효모와 실시예 1에서 제작한 인위적 세포 소기관 조절능을 가진 재조합 효모 중 퍼옥시좀 자기소화 관련 단백질 ATG36 (ATG36)을 제거한 효모인 PX1에 도입시켜 형질전환을 수행하였으며, 각각 대조군 CEN-KRN과 형질전환된 PX1- KRN로 명명하였다. The transformant cassette GPD - tHMG1 - CYC1 prepared in the above 3.1 was transformed into wild-type yeast and
형질전환된 각 재조합 효모의 단일 콜로니를 YPD배지 (10g/L 효소추출물(yeast extract), 20g/L 펩톤 (peptone), 및 20g/L 포도당(glucose)) 5㎖에 접종하여 30℃에서 24시간 진탕 배양하였으며, 얻어진 배양액 5㎖씩을 각각 YPD배지 (10g/L 효소추출물(yeast extract), 20g/L 펩톤 (peptone), 및 20g/L 포도당(glucose)) 50㎖에 접종한 후 30℃에서 168시간 진탕 배양하였다. 이 후 배양액 1㎖씩을 취하여 분광광도계를 이용해 600 nm의 파장에서 흡광도를 측정한 후 희석배수를 곱하여 균체량을 확인하였다. 또한, 배양된 각 50㎖ 배지를 원심분리하여 균체와 배지를 분리한 후 균체를 5㎖ 100% 아세톤(acetone)으로 풀어 발현된 카우린을 추출하고, 10㎖ 헥산(hexane)과 물(H2O)로 카우린 층을 나눠 카우린을 분리시켰다. 분리된 카우린을 유리시험관으로 옮긴 후 고압건조기를 이용해 30분간 건조 시키고, 건조된 카우린 추출물을 1㎖ 헥산에 녹인 다음 1㎕의 추출물을 기체크로마토그래피(GC) 질량분광법 시스템(MS)을 이용해 균체의 카우린을 측정하였다. 배지의 경우 10㎖ 배지에 10㎖ 헥산을 넣어 카우린 층을 나눠 카우린을 분리시켰다. 분리된 카우린을 유리시험관으로 옮긴 후 고압건조기를 이용해 30분간 건조 시키고, 건조된 카우린 추출물을 1㎖ 헥산에 녹인 다음 1㎕의 추출물을 기체크로마토그래피(GC) 질량분광법 시스템(MS)을 이용해 배지의 카우린을 측정하였다. 측정값을 검량선을 통해 얻은 방정식에 대입하였고, 희석 배수를 계산하여 카우린양을 계산하였다. 이때, 검량선 작성을 위해서 자체 카우린을 정제하여 무게를 측정한 후, 헥산에 용해시키고 각각 다른 농도로 헥산에 희석하여 기체크로마토그래피 질량분광법 시스템을 이용해 카우린 양을 측정하고 이를 이용해 표준 검량선을 작성하였다. 실험에 사용한 기체크로마토그래피 조건은 하기와 같다. A single colony of each transformed recombinant yeast was inoculated in 5 ml of YPD medium (10 g / L yeast extract, 20 g / L peptone, and 20 g / L glucose) Each 5 ml of the obtained culture was inoculated into 50 ml of YPD medium (10 g / L yeast extract, 20 g / L peptone, and 20 g / L glucose) Time shake culture. After that, 1 ml of each culture was taken and the absorbance was measured at a wavelength of 600 nm using a spectrophotometer, and the amount of the cells was determined by multiplying by the dilution factor. In addition, each 50 ml culture medium was centrifuged to separate the cells and the culture medium. The cells were then extracted with 5 ml of 100% acetone to extract the expressed kaurin, and the cells were extracted with 10 ml of hexane and water (H 2 O) to separate kaolin. The separated kaurin was transferred to a glass test tube and dried for 30 minutes using a high-pressure dryer. The dried kaurin extract was dissolved in 1 ml of hexane, and 1 μl of the extract was analyzed by gas chromatography (GC) mass spectrometry (MS) The kaurin content of the cells was measured. For the medium, 10 ml of hexane was added to a 10 ml medium to separate the kaolin layer to separate kaolin. The separated kaurin was transferred to a glass test tube and dried for 30 minutes using a high-pressure dryer. The dried kaurin extract was dissolved in 1 ml of hexane, and 1 μl of the extract was analyzed by gas chromatography (GC) mass spectrometry (MS) The kaolin of the medium was measured. The measured value was substituted into the equation obtained from the calibration curve, and the amount of kaolin was calculated by calculating the dilution factor. In order to prepare the calibration curve, the own kaurin was purified and its weight was measured, and it was dissolved in hexane, diluted with hexane at different concentrations, and the amount of kaolin was measured using a gas chromatography mass spectrometry system. Respectively. The gas chromatographic conditions used in the experiment are as follows.
- 기체크로마토그래피: 시료주입장치(auto-sampler)가 장착된 에이질런트 테크놀로지 7890A (Agilent Technologies 7890C) 모델- Gas chromatography: Agilent Technologies 7890A (Agilent Technologies 7890C) model with auto-sampler
- 질량분광법 시스템: 에이질런트 테크놀로지 5975C (Agilent Technologies 5975C) 모델- Mass spectrometry system: Agilent Technologies 5975C (Agilent Technologies 5975C) model
- 컬럼: Agilent HP5-MS (0.25 mm × 30 m, 0.25-micron) Column: Agilent HP5-MS (0.25 mm x 30 m, 0.25-micron)
- 전자 이온화 모드: 70ev- Electron ionization mode: 70ev
- 속도: 1.0 ㎖/분- Rate: 1.0 ml / min
- 시료주입 온도: 80℃- Sample injection temperature: 80 ℃
- 오븐 온도: 80℃ 1분유지 후 15℃/분의 속도로 245℃까지 가열, 이후 5℃/분의 속도로 300℃까지 가열 - oven temperature: maintained at 80 캜 for 1 minute, then heated to 245 캜 at a rate of 15 캜 / minute, then heated to 300 캜 at a rate of 5 캜 / minute
- 시료주입량: 1㎕ (Splitless mode)- Sample injection amount: 1μ (Splitless mode)
- 검출: MS 결과 (90 m/z ~ 600 m/z)- Detection: MS results (90 m / z to 600 m / z)
상기 방법으로 확인된, 인위적 세포 소기관 조절을 통해 향상된 카우린의 생산능을 가진 재조합 효모의 균체량 및 각 카우린의 생산량을 하기 표 6 및 도 7에 나타내었다.The amount of the recombinant yeast having the ability to produce kaolin improved through artificial cell organellar control and the amount of each kaurin produced, confirmed by the above method, are shown in Table 6 and FIG.
(OD600)Maximal device
(OD600)
절대정량값 (mg/L)Kaurin
Absolute quantitative value (mg / L)
상기 표 6 및 도 7 에 나타낸 바와 같이, 실시예 1의 인위적 세포 소기관 조절능을 가진 재조합 효모에 지베렐린 대사물질 중 하나인 카우린을 생산하는 효소인 개량된 하이드록시메틸글루타릴-CoA 환원효소, 제라닐제라닐 피로인산 합성효소 및 코파릴 피로인산 및 카우린 합성효소를 암호화 하는 유전자 조합이 발현되는 형질전환 카세트 GPD - tHMG1 - CYC1 , TEF1 - CrtE - CYC1 , 및 PGK1 - CDPS /KS- TEF2를 도입하는 경우, 동일한 형질전환 카세트가 도입된 야생형 효모와 비교하여, 비록 세포 성장은 다소 감소하였으나 (도 7A) 카우린 생산량이 최대 120% 까지 더욱 증가(도 7B)하였으며, 이를 통해 인위적 세포 소기관 조절능을 가진 재조합 효모를 이용하는 경우, 높은 지베렐린 대사물질 생산성을 나타냄을 확인하였다.As shown in Table 6 and FIG. 7, in the recombinant yeast having an artificial cellular organelles regulating ability of Example 1, an improved hydroxymethylglutaryl-CoA reductase enzyme, which is an enzyme that produces kaurin, one of the gibberellin metabolites , Transgenic cassettes GPD - tHMG1 - CYC1 , TEF1 - CrtE - CYC1 , and PGK1 - CDPS / KS- TEF2 expressing a gene encoding a geranyl geranyl pyrophosphate synthase and a gene encoding a coaryl pyrophosphate and a kaurin synthase (Fig. 7A), kaurin production was further increased up to 120% (Fig. 7B), compared with the wild-type yeast in which the same transfection cassette was introduced, When the recombinant yeast having the regulatory ability was used, it was confirmed that the productivity of the high gibberellin metabolite was exhibited.
SEQUENCE LISTING <110> AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION <120> Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same <130> AJOU1-85P-1 <150> KR10-2017-0181134 <151> 2017-12-27 <160> 38 <170> PatentIn version 3.2 <210> 1 <211> 33 <212> DNA <213> Artificial <220> <223> PEX34 forward primer <400> 1 agcggatcca aaatggtttc gaagaaaaat acg 33 <210> 2 <211> 32 <212> DNA <213> Artificial <220> <223> PEX34 reverse primer <400> 2 tacgtcgact tatacaatta ttctacaaag tg 32 <210> 3 <211> 66 <212> DNA <213> Artificial <220> <223> ATG36 Del cassette forward primer <400> 3 tgtattcagg gcttaaaata ctaaaatttg gtggtcagta cagttcatta gacgttgtaa 60 aacgac 66 <210> 4 <211> 68 <212> DNA <213> Artificial <220> <223> ATG36 Del cassette reverse primer <400> 4 aactgatggt gttcggacaa cgttttagaa tgagggtatc taactttctt caggaaacag 60 ctatgacc 68 <210> 5 <211> 70 <212> DNA <213> Artificial <220> <223> PEX11 Del - PEX34 O/E cassette forward primer <400> 5 tgtctacatc tactacttca aagacttcat caagtaatag tataatcaat gacgttgtaa 60 aacgacggcc 70 <210> 6 <211> 72 <212> DNA <213> Artificial <220> <223> PEX11 Del - PEX34 O/E cassette reverse primer <400> 6 atcaaacata agcggagaat agccaaataa aaaaaaagat gaaaagaaag cacacaggaa 60 acagctatga cc 72 <210> 7 <211> 70 <212> DNA <213> Artificial <220> <223> PEX34 O/E cassette forward primer <400> 7 ccaaaatttg tttactaaaa acacatgtgg atatcttgac tgatttttcc gacgttgtaa 60 aacgacggcc 70 <210> 8 <211> 72 <212> DNA <213> Artificial <220> <223> PEX34 O/E cassette reverse primer <400> 8 gctctaattt gtgagtttag tatacatgca tttacttata atacagtttt cacacaggaa 60 acagctatga cc 72 <210> 9 <211> 70 <212> DNA <213> Artificial <220> <223> POT1-EGFP cassette forward primer <400> 9 gtatgtgtat cggtactggt atgggtgccg ccgccatctt tattaaagaa cggatccccg 60 ggttaattaa 70 <210> 10 <211> 70 <212> DNA <213> Artificial <220> <223> POT1-EGFP cassette reverse primer <400> 10 ttttaatact tgataatagt taatattctc cctttttatt atgctcatat gaattcgagc 60 tcgtttaaac 70 <210> 11 <211> 32 <212> DNA <213> Artificial <220> <223> tHMG1 forward primer <400> 11 cggcggccgc aaaatgtcta ttccagaaac tc 32 <210> 12 <211> 28 <212> DNA <213> Artificial <220> <223> tHMG1 reverse primer <400> 12 gcactagttt atttagaagt gtcaacaa 28 <210> 13 <211> 29 <212> DNA <213> Artificial <220> <223> GPD-tHMG1 forward primer <400> 13 gcctgcagag tttatcatta tcaatactc 29 <210> 14 <211> 25 <212> DNA <213> Artificial <220> <223> GPD-tHMG1 reverse primer <400> 14 cgcgtcgacg gccgcaaatt aaagc 25 <210> 15 <211> 71 <212> DNA <213> Artificial <220> <223> GPD-tHMG1-LEU2forward primer <400> 15 acgttggtca agaaatcaca gccgaagcca ttaaggttct taaagctatt agtttatcat 60 tatcaatact c 71 <210> 16 <211> 71 <212> DNA <213> Artificial <220> <223> GPD-tHMG1-LEU2 reverse primer <400> 16 atggccttac cttcttcagg caagttcaat gacaatttca acatcattgc attatcatga 60 cattaaccta t 71 <210> 17 <211> 29 <212> DNA <213> Artificial <220> <223> CrtE forward primer <400> 17 gactagtaaa aatggattac gcgaacatc 29 <210> 18 <211> 26 <212> DNA <213> Artificial <220> <223> CrtE reverse primer <400> 18 ccccccgggt cacagaggga tatcgg 26 <210> 19 <211> 31 <212> DNA <213> Artificial <220> <223> CrtYB forward primer <400> 19 cgggatccaa aatgacggct ctcgcatatt a 31 <210> 20 <211> 28 <212> DNA <213> Artificial <220> <223> CrtYB reverse primer <400> 20 acgcgtcgac ttactgccct tcccatcc 28 <210> 21 <211> 33 <212> DNA <213> Artificial <220> <223> CrtI forward primer <400> 21 cgggatccaa aatgggaaaa gaacaagatc agg 33 <210> 22 <211> 31 <212> DNA <213> Artificial <220> <223> CrtI reverse primer <400> 22 acgcgtcgac tcagaaagca agaacaccaa c 31 <210> 23 <211> 17 <212> DNA <213> Artificial <220> <223> ypl062w forward primer or ROX1 forward primer or yjl064w forward primer <400> 23 gaattggagc tcactcg 17 <210> 24 <211> 40 <212> DNA <213> Artificial <220> <223> ypl062w reverse primer <400> 24 cggcgcgccc accctctttt gatcatttat ctttcactgc 40 <210> 25 <211> 41 <212> DNA <213> Artificial <220> <223> ypl062w forward primer <400> 25 aaaagagggt gggcgcgccg gttttagagc tagaaatagc a 41 <210> 26 <211> 18 <212> DNA <213> Artificial <220> <223> ypl062w reverse primer or ROX1 reverse primer or yjl064w reverse primer <400> 26 gaacaaaagc tggtaccg 18 <210> 27 <211> 40 <212> DNA <213> Artificial <220> <223> ROX1 reverse primer <400> 27 ccccctctat taccttctct gatcatttat ctttcactgc 40 <210> 28 <211> 41 <212> DNA <213> Artificial <220> <223> ROX1 forward primer <400> 28 agagaaggta atagaggggg gttttagagc tagaaatagc a 41 <210> 29 <211> 40 <212> DNA <213> Artificial <220> <223> yjl064w forward primer <400> 29 ggtgctgaca catgagtccc gatcatttat ctttcactgc 40 <210> 30 <211> 41 <212> DNA <213> Artificial <220> <223> yjl064w forward primer <400> 30 gggactcatg tgtcagcacc gttttagagc tagaaatagc a 41 <210> 31 <211> 65 <212> DNA <213> Artificial <220> <223> TEF1-CrtE-CYC1 forward primer <400> 31 caggtcagga actgccgtca catacgacac tgcccctcac gtaagggcaa gcgcgcaatt 60 aaccc 65 <210> 32 <211> 68 <212> DNA <213> Artificial <220> <223> TEF1-CrtE-CYC1 reverse primer <400> 32 aatccccctc accccgaatt tattacgaat ttgcccacat ggtcggtgct atagggcgaa 60 ttgggtac 68 <210> 33 <211> 67 <212> DNA <213> Artificial <220> <223> PGK1-CrtYB-CYC1 forward primer or PGK1-CDPS/KS-TEF2 forward primer <400> 33 ccagaaaata ctaatacttc ttcacacaaa agaacgcagt tagacaatcc aagcgcgcaa 60 ttaaccc 67 <210> 34 <211> 66 <212> DNA <213> Artificial <220> <223> PGK1-CDPS/KS-TEF2 reverse primer or PGK1-CrtYB-CYC1 reverse primer <400> 34 gttaaaggga atatagtata atataatata acggaaagaa gaaatgggca gattgtactg 60 agagtg 66 <210> 35 <211> 67 <212> DNA <213> Artificial <220> <223> PGK1-CrtI-ADH2 forward primer <400> 35 cggagccgta tcgttcacca cataggcgga gtaaacttca ttagggggcg cgcgcaatta 60 accctca 67 <210> 36 <211> 66 <212> DNA <213> Artificial <220> <223> PGK1-CrtI-ADH2 reverse primer <400> 36 cagaagaaac aagagagaat agcgtcagga tagctcgctc gatgtgacac tatagggcga 60 attggg 66 <210> 37 <211> 29 <212> DNA <213> Artificial <220> <223> CDPS/KS forward primer <400> 37 ggactagtca aaatgcctgg caaaatcga 29 <210> 38 <211> 30 <212> DNA <213> Artificial <220> <223> CDPS/KS reverse primer <400> 38 ccgctcgagt cacttcatgc tgcttgaaag 30 SEQUENCE LISTING <110> AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION <120> Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same <130> AJOU1-85P-1 <150> KR10-2017-0181134 <151> 2017-12-27 <160> 38 <170> PatentIn version 3.2 <210> 1 <211> 33 <212> DNA <213> Artificial <220> <223> PEX34 forward primer <400> 1 agcggatcca aaatggtttc gaagaaaaat acg 33 <210> 2 <211> 32 <212> DNA <213> Artificial <220> <223> PEX34 reverse primer <400> 2 tacgtcgact tatacaatta ttctacaaag tg 32 <210> 3 <211> 66 <212> DNA <213> Artificial <220> <223> ATG36 Del cassette forward primer <400> 3 tgtattcagg gcttaaaata ctaaaatttg gtggtcagta cagttcatta gacgttgtaa 60 aacgac 66 <210> 4 <211> 68 <212> DNA <213> Artificial <220> <223> ATG36 Del cassette reverse primer <400> 4 aactgatggt gttcggacaa cgttttagaa tgagggtatc taactttctt caggaaacag 60 ctatgacc 68 <210> 5 <211> 70 <212> DNA <213> Artificial <220> <223> PEX11 Del - PEX34 O / E cassette forward primer <400> 5 tgtctacatc tactacttca aagacttcat caagtaatag tataatcaat gacgttgtaa 60 aacgacggcc 70 <210> 6 <211> 72 <212> DNA <213> Artificial <220> <223> PEX11 Del - PEX34 O / E cassette reverse primer <400> 6 atcaaacata agcggagaat agccaaataa aaaaaaagat gaaaagaaag cacacaggaa 60 acagctatga cc 72 <210> 7 <211> 70 <212> DNA <213> Artificial <220> <223> PEX34 O / E cassette forward primer <400> 7 ccaaaatttg tttactaaaa acacatgtgg atatcttgac tgatttttcc gacgttgtaa 60 aacgacggcc 70 <210> 8 <211> 72 <212> DNA <213> Artificial <220> <223> PEX34 O / E cassette reverse primer <400> 8 gctctaattt gtgagtttag tatacatgca tttacttata atacagtttt cacacaggaa 60 acagctatga cc 72 <210> 9 <211> 70 <212> DNA <213> Artificial <220> <223> POT1-EGFP cassette forward primer <400> 9 gtatgtgtat cggtactggt atgggtgccg ccgccatctt tattaaagaa cggatccccg 60 ggttaattaa 70 <210> 10 <211> 70 <212> DNA <213> Artificial <220> <223> POT1-EGFP cassette reverse primer <400> 10 ttttaatact tgataatagt taatattctc cctttttatt atgctcatat gaattcgagc 60 tcgtttaaac 70 <210> 11 <211> 32 <212> DNA <213> Artificial <220> <223> tHMG1 forward primer <400> 11 cggcggccgc aaaatgtcta ttccagaaac tc 32 <210> 12 <211> 28 <212> DNA <213> Artificial <220> <223> tHMG1 reverse primer <400> 12 gcactagttt atttagaagt gtcaacaa 28 <210> 13 <211> 29 <212> DNA <213> Artificial <220> <223> GPD-tHMG1 forward primer <400> 13 gcctgcagag tttatcatta tcaatactc 29 <210> 14 <211> 25 <212> DNA <213> Artificial <220> <223> GPD-tHMG1 reverse primer <400> 14 cgcgtcgacg gccgcaaatt aaagc 25 <210> 15 <211> 71 <212> DNA <213> Artificial <220> GPD-tHMG1-LEU2 forward primer <400> 15 acgttggtca agaaatcaca gccgaagcca ttaaggttct taaagctatt agtttatcat 60 tatcaatact c 71 <210> 16 <211> 71 <212> DNA <213> Artificial <220> GPD-tHMG1-LEU2 reverse primer <400> 16 atggccttac cttcttcagg caagttcaat gacaatttca acatcattgc attatcatga 60 cattaaccta t 71 <210> 17 <211> 29 <212> DNA <213> Artificial <220> <223> CrtE forward primer <400> 17 gactagtaaa aatggattac gcgaacatc 29 <210> 18 <211> 26 <212> DNA <213> Artificial <220> <223> CrtE reverse primer <400> 18 ccccccgggt cacagaggga tatcgg 26 <210> 19 <211> 31 <212> DNA <213> Artificial <220> <223> CrtYB forward primer <400> 19 cgggatccaa aatgacggct ctcgcatatt a 31 <210> 20 <211> 28 <212> DNA <213> Artificial <220> <223> CrtYB reverse primer <400> 20 acgcgtcgac ttactgccct tcccatcc 28 <210> 21 <211> 33 <212> DNA <213> Artificial <220> <223> CrtI forward primer <400> 21 cgggatccaa aatgggaaaa gaacaagatc agg 33 <210> 22 <211> 31 <212> DNA <213> Artificial <220> <223> CrtI reverse primer <400> 22 acgcgtcgac tcagaaagca agaacaccaa c 31 <210> 23 <211> 17 <212> DNA <213> Artificial <220> <223> ypl062w forward primer or ROX1 forward primer or yjl064w forward primer <400> 23 gaattggagc tcactcg 17 <210> 24 <211> 40 <212> DNA <213> Artificial <220> <223> ypl062w reverse primer <400> 24 cggcgcgccc accctctttt gatcatttat ctttcactgc 40 <210> 25 <211> 41 <212> DNA <213> Artificial <220> <223> ypl062w forward primer <400> 25 gt; <210> 26 <211> 18 <212> DNA <213> Artificial <220> <223> ypl062w reverse primer or ROX1 reverse primer or yjl064w reverse primer <400> 26 gaacaaaagc tggtaccg 18 <210> 27 <211> 40 <212> DNA <213> Artificial <220> <223> ROX1 reverse primer <400> 27 ccccctctat taccttctct gatcatttat ctttcactgc 40 <210> 28 <211> 41 <212> DNA <213> Artificial <220> <223> ROX1 forward primer <400> 28 agagaaggta atagaggggg gttttagagc tagaaatagc a 41 <210> 29 <211> 40 <212> DNA <213> Artificial <220> <223> yjl064w forward primer <400> 29 ggtgctgaca catgagtccc gatcatttat ctttcactgc 40 <210> 30 <211> 41 <212> DNA <213> Artificial <220> <223> yjl064w forward primer <400> 30 gggactcatg tgtcagcacc gttttagagc tagaaatagc a 41 <210> 31 <211> 65 <212> DNA <213> Artificial <220> <223> TEF1-CrtE-CYC1 forward primer <400> 31 caggtcagga actgccgtca catacgacac tgcccctcac gtaagggcaa gcgcgcaatt 60 aaccc 65 <210> 32 <211> 68 <212> DNA <213> Artificial <220> <223> TEF1-CrtE-CYC1 reverse primer <400> 32 aatccccctc accccgaatt tattacgaat ttgcccacat ggtcggtgct atagggcgaa 60 ttgggtac 68 <210> 33 <211> 67 <212> DNA <213> Artificial <220> PGK1-CrtYB-CYC1 forward primer or PGK1-CDPS / KS-TEF2 forward primer <400> 33 ccagaaaata ctaatacttc ttcacacaaa agaacgcagt tagacaatcc aagcgcgcaa 60 ttaaccc 67 <210> 34 <211> 66 <212> DNA <213> Artificial <220> ≪ 223 > PGK1-CDPS / KS-TEF2 reverse primer or PGK1-CrtYB-CYC1 reverse primer <400> 34 gttaaaggga atatagtata atataatata acggaaagaa gaaatgggca gattgtactg 60 agagtg 66 <210> 35 <211> 67 <212> DNA <213> Artificial <220> <223> PGK1-CrtI-ADH2 forward primer <400> 35 cggagccgta tcgttcacca cataggcgga gtaaacttca ttagggggcg cgcgcaatta 60 accctca 67 <210> 36 <211> 66 <212> DNA <213> Artificial <220> ≪ 223 > PGK1-CrtI-ADH2 reverse primer <400> 36 cagaagaaac aagagagaat agcgtcagga tagctcgctc gatgtgacac tatagggcga 60 attggg 66 <210> 37 <211> 29 <212> DNA <213> Artificial <220> <223> CDPS / KS forward primer <400> 37 ggactagtca aaatgcctgg caaaatcga 29 <210> 38 <211> 30 <212> DNA <213> Artificial <220> <223> CDPS / KS reverse primer <400> 38 ccgctcgagt cacttcatgc tgcttgaaag 30
Claims (13)
PEX34 (Peroxisomal membrane protein 34) overexpression, PEX11 (Peroxisomal membrane protein 11) gene deletion and ATG36 And a deletion of a gene encoding a peroxisome autophagy-related protein (36) gene in a cell organelle-transformed recombinant yeast.
i) ATG36 유전자가 결실된 재조합 효모
ii) PEX34 유전자가 과발현된 재조합 효모
iii) PEX11 유전자 결실 및 PEX34 유전자가 과발현된 재조합 효모 및
iv) PEX11 유전자 결실, ATG36 유전자 결실 및 PEX34 유전자가 과발현된 재조합 효모로 이루어진 군에서 선택된 1종의 효모인, 세포 소기관이 변이된 재조합 효모.
2. The method according to claim 1, wherein the recombinant yeast is
i) ATG36 Recombinant yeast lacking the gene
ii) PEX34 Recombinant yeast overexpressing the gene
iii) PEX11 Gene deletion and PEX34 Recombinant yeast overexpressing the gene and
iv) PEX11 Gene deletion, ATG36 gene deletion and PEX34 Wherein the recombinant yeast is a yeast selected from the group consisting of a recombinant yeast overexpressing the gene and a cell organellated mutant.
The method of claim 1, wherein the PEX34 Gene, PEX11 Wherein the gene and the ATG36 gene are derived from Saccharomyces cerevisiae.
The recombinant yeast according to claim 1, wherein the recombinant yeast is selected from the group consisting of S. cerevisiae, S. bayanus, S. boulardii, S. bulderi, S. cariocanus, S. cariocus, S. chevalieri, and S. cariocanus, S. dairenensis, S. ellipsoideus, S. eubayanus, S. exiguus, and S. cerevisiae, For example, S. florentinus, S. kluyveri, S. martiniae, S. monacensis, and S. cerevisiae, S. norbensis, S. paradoxus, S. pastorius, and the like, an S. cerevisiae, S. spencerorum, S. turicensis, S. unisporus, S saccharomyces utavorum (S wherein the recombinant yeast is one selected from the group consisting of yeast, uvarum, and S. zonatus.
5. The recombinant yeast according to any one of claims 1 to 4, wherein the mutation of the cell organelles is an increase in the number or size of peroxisome.
i) tHMG1 (truncated hydroxy-methyl glutaryl-CoA reductase), CrtE (Geranylgeranyl pyrophosphate synthase), CrtYB (Phytoene synthase-lycopene cyclase) 및 CrtI (Phytoene desaturase) 유전자 세트 및
ii) tHMG1, CrtE 및 CDPS /KS (ent-copalyl diphosphate/kaurene synthase) 유전자 세트로 이루어진 군에서 선택된 1종의 유전자 세트가 도입된 아이소프레노이드 생산성이 증대된 재조합 효모.
The recombinant yeast of claim 1,
i) tHMG1 (truncated hydroxy-methyl glutaryl-CoA reductase) , CrtE (Geranylgeranyl pyrophosphate synthase), CrtYB (Phytoene synthase-lycopene cyclase) and CrtI ( Phytoene desaturase) Gene set and
ii) tHMG1, CrtE and And a set of genes selected from the group consisting of CDPS / KS (ent-copalyl diphosphate / kaurene synthase) gene sets.
7. The recombinant yeast according to claim 6, wherein the isoprenoid is beta carotene, kaurin, carotinoid or gibberellin.
7. The method of claim 6, wherein the tHMGl is It is derived from Saccharomyces cerevisiae. The CrtE, CrtYB And CrtI Wherein the recombinant yeast is derived from xanthophyllomyces dendrorhous , and wherein the CDPS / KS is derived from Fusarium fujikuroi .
The method of claim 6, wherein the recombinant yeast is i) tHMG1 (truncated HMG1), CrtE, CrtYB and A recombinant yeast with increased isoprenoid productivity, wherein the isoformic acid is a carotenoid, wherein the CrtI gene set is introduced.
10. The recombinant yeast according to claim 9, wherein the recombinant yeast is increased in beta-carotene productivity.
7. The method according to claim 6, wherein the recombinant yeast is selected from the group consisting of tHMG1 , CrtE And A recombinant yeast with enhanced isoprenoid productivity, wherein the isoprenoid is gibberellin, wherein the CDPS / KS gene set is introduced.
12. The recombinant yeast according to claim 11, wherein the recombinant yeast is increased in kaolin productivity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170181134 | 2017-12-27 | ||
KR20170181134 | 2017-12-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200042599A Division KR102170444B1 (en) | 2017-12-27 | 2020-04-08 | Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190079575A true KR20190079575A (en) | 2019-07-05 |
KR102170446B1 KR102170446B1 (en) | 2020-10-28 |
Family
ID=67067822
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180170019A KR102170446B1 (en) | 2017-12-27 | 2018-12-27 | Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same |
KR1020200042599A KR102170444B1 (en) | 2017-12-27 | 2020-04-08 | Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200042599A KR102170444B1 (en) | 2017-12-27 | 2020-04-08 | Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR102170446B1 (en) |
WO (1) | WO2019132510A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021204338A1 (en) | 2020-04-08 | 2021-10-14 | Københavns Universitet | Production of geranyl diphosphate-derived compounds |
WO2024189183A1 (en) | 2023-03-16 | 2024-09-19 | Evodiabio Aps | Optimized production of branch point compounds and derivatives using alternative isopentenyl diphosphate-supplying pathways |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113624855B (en) * | 2020-12-29 | 2023-05-19 | 晨光生物科技集团股份有限公司 | Method for detecting residual quantity of n-hexane and acetone solvents in crystal lycopene |
CN116286880B (en) * | 2023-02-09 | 2024-04-30 | 昆明理工大学 | A peroxisome proliferation factor gene RkPEX11 and its use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214133A2 (en) * | 2016-06-06 | 2017-12-14 | Provivi, Inc. | Semi-biosynthetic production of fatty alcohols and fatty aldehydes |
-
2018
- 2018-12-26 WO PCT/KR2018/016663 patent/WO2019132510A2/en active Application Filing
- 2018-12-27 KR KR1020180170019A patent/KR102170446B1/en active IP Right Grant
-
2020
- 2020-04-08 KR KR1020200042599A patent/KR102170444B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214133A2 (en) * | 2016-06-06 | 2017-12-14 | Provivi, Inc. | Semi-biosynthetic production of fatty alcohols and fatty aldehydes |
Non-Patent Citations (1)
Title |
---|
Alison M Motley 등. The EMBO Journal. Vol. 31, 페이지 2852-2868 (2012.) 1부.* * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021204338A1 (en) | 2020-04-08 | 2021-10-14 | Københavns Universitet | Production of geranyl diphosphate-derived compounds |
WO2024189183A1 (en) | 2023-03-16 | 2024-09-19 | Evodiabio Aps | Optimized production of branch point compounds and derivatives using alternative isopentenyl diphosphate-supplying pathways |
Also Published As
Publication number | Publication date |
---|---|
WO2019132510A2 (en) | 2019-07-04 |
KR102170444B1 (en) | 2020-10-28 |
WO2019132510A3 (en) | 2019-08-15 |
KR20200039645A (en) | 2020-04-16 |
KR102170446B1 (en) | 2020-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kildegaard et al. | Engineering of Yarrowia lipolytica for production of astaxanthin | |
US10392635B2 (en) | Production of tetrahydrocannabinolic acid in yeast | |
Zhou et al. | Alleviation of metabolic bottleneck by combinatorial engineering enhanced astaxanthin synthesis in Saccharomyces cerevisiae | |
KR102170444B1 (en) | Recombinant yeast with artificial cellular organelles and producing method for isoprenoids with same | |
CN110484572B (en) | Method for increasing yield of saccharomyces cerevisiae nerolidol | |
Csernetics et al. | Expression of three isoprenoid biosynthesis genes and their effects on the carotenoid production of the zygomycete Mucor circinelloides | |
CA3137451A1 (en) | Methods and cells for microbial production of phytocannabinoids and phytocannabinoid precursors | |
US20240102030A1 (en) | Inducible Production-Phase Promoters for Coordinated Heterologous Expression in Yeast | |
US20180265897A1 (en) | Production of macrocyclic diterpenes in recombinant hosts | |
Li et al. | Heterologous production of α-Carotene in Corynebacterium glutamicum using a multi-copy chromosomal integration method | |
Mo et al. | Multi-level engineering of Saccharomyces cerevisiae for the synthesis and accumulation of retinal | |
CN115873836A (en) | Nerolidol synthetase and application thereof | |
Kim et al. | Production of (−)-α-bisabolol in metabolically engineered Saccharomyces cerevisiae | |
Csernetics et al. | Expression of Xanthophyllomyces dendrorhous cytochrome-P450 hydroxylase and reductase in Mucor circinelloides | |
EP3234105B1 (en) | Methods for tuning carotenoid production levels and compositions in rhodosporidium and rhodotorula genera | |
CN115305254B (en) | A kind of terpenoid chassis microorganism and engineering bacteria and its construction method and application | |
CN112608936B (en) | Promoter for regulating and controlling expression of exogenous gene of yeast, regulating and controlling method and application thereof | |
KR101625898B1 (en) | Recombinant microorganism with mevalonate or mevalonolactone production ability, and method for preparing mevalonate or mevalonolactone using the same | |
CN115927147A (en) | Method for improving antioxidant activity of lactococcus lactis and application thereof | |
US20060141557A1 (en) | Production of canthaxanthin by phaffia | |
CN118813433A (en) | Genetically engineered bacteria for producing beta-carotene, preparation method and application thereof | |
KR102646404B1 (en) | Microbial biosynthesis of retinoic acid | |
NL2024578B1 (en) | Recombinant fungal cell | |
Brown et al. | Metabolic engineering of Neurospora crassa for increasing carotenoids synthesis | |
Liao et al. | MpDLDH gene is crucial for regulating growth and pigment biosynthesis through acetyl-CoA modulation in Monascus purpureus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20181227 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200109 Patent event code: PE09021S01D |
|
A107 | Divisional application of patent | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20200408 Patent event code: PA01071R01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20201019 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20201021 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20201021 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |